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Abstract:  
Background: Malaria is one of the most devastating diseases with lethal outcome of more 
than one million humans per year. This study intended for a novel drug discovery in order 
to prevent the Plasmodium related resistance focusing on identifying and targeting host 
factors essential for pathogen entry, survival and proliferation. The innovative methods 
involve induction of suicidal death in infected erythrocytes (eryptosis) and recognition by 
the spleen macrophages to get rid of the pathogen and prevent the further course of the 
disease. Eryptosis is characterized by cell shrinkage, membrane blebbing and cell 
membrane phospholipid scrambling with phosphatidylserine exposure at the cell surface. 
Phosphatidylserine-exposing erythrocytes are identified by macrophages which engulf and 
degrade the eryptotic cells.  
Objectives: The study has been performed to explore whether the administration of 
amphotericin B or gum Arabic may modify the course of malaria and survival of 
Plasmodium berghei -infected mice. 
Materials and methods: Human erythrocytes were infected in vitro with Plasmodium 
falciparum (strain BinH) in the absence and presence of amphotericin B or butyrate, 
parasitaemia determined utilizing Syto16, cytosolic calcium estimated from fluo3 
fluorescence intensity, phosphatidylserine exposure estimated from annexin V-binding and 
cell volume from forward scatter in fluorescence activated cell sorting analysis. Mice were 
infected with Plasmodium berghei ANKA by injecting parasitized murine erythrocytes (1 
× 106) intraperitoneally. Where indicated amphotericin B (1.4 mg/kg b.w.) was 
administered subcutaneously from the eighth day of infection for three successive days. 
10% gum Arabic dissolved in tap water started from the day of infection for the other 
group of mice. Preparations of gum Arabic were refreshed every day during the treatment. 
Results: Amphotericin B during in vitro infection of human erythrocytes with P. 
falciparum,  increased phosphatidylserine exposure, decreased forward scatter and 
significantly increases cytosolic calcium activity. Amphotericin B did not significantly 
alter intraerythrocytic DNA/RNA amplification only at 1 µM but significantly (≥0.01 µM) 
decreased in vitro parasitemia. Erythrocytes from amphotericin B treated mice were more 
rapidly cleared from circulating blood than non-treated erythrocytes. Moreover, 
parasitemia in P. berghei infected mice was significantly decreased (from 50.61% to 
39.36% of circulating erythrocytes 20 days after infection) and mouse survival 
VIII 
 
significantly enhanced (from 0% to 80% 27 days after infection) upon administration of 
amphotericin B (1.4 mg/kg b. w) subcutaneously from the eighth day of infection. 
In the other in vitro part of this study butyrate which is one of the important gum Arabic 
fermentation products, significantly (≥0.5 mM) decreased the proliferation of P. 
falciparum. On the other hand it influences intraerythrocytic DNA/RNA amplification only 
at 10 mM concentration. Butyrate was significantly increased phosphatidylserine exposure, 
decreased forward scatter and significantly increases cytosolic calcium activity. Most 
importantly, gum Arabic treatment (10% in drinking water from the day of infection) 
resulted in a significant decrease of parasitemia (from 43.6 ± 4.39 and 58.08) and increased 
the survival of P. berghei-infected mice (70% of the gum Arabic-treated animals survived 
the infection for more than 26 days after infection). 
Conclusions: In conclusion amphotericin B and gum Arabic stimulate the erythrocytic 
machinery responsible for the eryptosis following infection with Plasmodium. The 
acceleration of eryptosis precedes the full intraerythrocytic maturation of the pathogen, 
thus prevents the further lethal course of the disease and fosters host survival during 
malaria. The revelations defend that the stimulation of eryptosis in infected erythrocytes is 
a host dependent mechanism to combat against infection. The experimental results 
indicated that the stimulation of eryptosis in infected erythrocytes is not only a host 
dependent defense mechanism that can be used as a novel approach to prevent the chances 
of resistance in plasmodia. 
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
ﺔ هﺬﻩ اﻟﺪراﺳ. ﻓﻲ وﻓﺎة أآﺜﺮ ﻣﻦ ﻣﻠﻴﻮن اﻧﺴﺎن ﺳﻨﻮﻳﺎ و ﺗﺘﺴﺒﺐ  اﻟﻤﻼرﻳﺎ هﻲ واﺣﺪة ﻣﻦ أآﺜﺮ اﻷﻣﺮاض اﻟﻤﺪﻣﺮة: ﺧﻠﻔﻴﺔ
اﻟﻤﺨﺼﺼﺔ ﻻآﺘﺸﺎف أدوﻳﺔ ﺟﺪﻳﺪة ﻣﻦ أﺟﻞ ﻣﻨﻊ ﻣﺴﺒﺒﺎت اﻟﻤﺮض اﻟﻤﻘﺎوﻣﺔ ﻟﻸدوﻳﺔ ذات اﻟﺼﻠﺔ ﻣﻊ اﻟﺘﺮآﻴﺰ ﻋﻠﻰ ﺗﺤﺪﻳﺪ 
هﺬﻩ اﻷﺳﺎﻟﻴﺐ اﻟﻤﺒﺘﻜﺮة . واﺳﺘﻬﺪاف ﻋﻮاﻣﻞ أﺳﺎﺳﻴﺔ ﻓﻲ ﺟﺴﻢ اﻟﻌﺎﺋﻞ ﺗﺘﻌﻠﻖ ﺑﺪﺧﻮل ﻣﺴﺒﺒﺎت اﻟﻤﺮض وﺑﻘﺎﺋﻬﺎ واﻧﺘﺸﺎرهﺎ
و ﺗﻌﺮف ﺗﻌﺮف اﻟﺨﻼﻳﺎ اﻟﺒﺎﻟﻌﺔ ﻓﻲ اﻟﻄﺤﺎل ﻋﻠﻴﻬﺎ  ء اﻟﻤﺼﺎﺑﺔﺗﻨﻄﻮي ﻋﻠﻰ ﺗﺤﺮﻳﺾ اﻟﻮﻓﺎة اﻻﻧﺘﺤﺎرﻳﺔ ﻟﻜﺮﻳﺎت اﻟﺪم اﻟﺤﻤﺮا
 اﻟﻮﻓﺎة اﻻﻧﺘﺤﺎرﻳﺔ ﻟﻜﺮﻳﺎت اﻟﺪم اﻟﺤﻤﺮاء وﺗﺘﻤﻴﺰ. ﻣﻦ أﺟﻞ اﻟﺘﺨﻠﺺ ﻣﻦ ﻣﺴﺒﺒﺎت اﻟﻤﺮض وﻣﻨﻊ اﻟﻤﺰﻳﺪ ﻣﻦ ﻣﺴﺎر اﻟﻤﺮض
 ﻳﻠﺴﻴﺮﻳﻦﺟﺰﻳﺌﺎت اﻟﻔﻮﺳﻔﺎﺗﻴﺪ و ﺑﻌﺜﺮة اﻟﺪهﻮن اﻟﻔﻮﺳﻔﻮرﻳﺔ ﻟﻐﺸﺎء اﻟﺨﻠﻴﺔ ﻣﻊ ﻋﺮض ﺑﺎﻧﻜﻤﺎش اﻟﺨﻠﻴﺔ ، واﻧﺘﻔﺎخ ﻏﺸﺎء اﻟﺨﻠﻴﺔ
ﻋﻠﻰ ﺳﻄﺢ اﻟﺨﻠﻴﺔ ﻣﻤﺎ ﻳﺆدي إﻟﻰ ﺳﻬﻮﻟﺔ اﻟﺘﻌﺮف ﻋﻠﻴﻬﺎ ﺑﻮاﺳﻄﺔ اﻟﺨﻼﻳﺎ اﻟﺒﺎﻟﻌﺔ و اﻟﺘﻲ ﺑﺪورهﺎ ﺗﻘﻮم ﺑﺈﻟﺘﻬﺎم ﺧﻼﻳﺎ اﻟﺪم 
  .اﻟﺤﻤﺮاء اﻟﻤﺼﺎﺑﺔ و ﺗﻜﺴﻴﺮهﺎ
ﺗﻬﺪف هﺬﻩ اﻟﺪراﺳﺔ ﻻﺳﺘﻜﺸﺎف ﻣﺎ اذا آﺎن إﻋﻄﺎء دواء اﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب أو اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ﻗﺪ ﻳﻌﺪل ﻣﺴﺎر : اﻷهﺪاف
  .ﺎء اﻟﻤﺘﺼﻮرة اﻟﺒﺮﺟﻴﻪ ﻓﻲ اﻟﻔﺌﺮان اﻟﻤﺼﺎﺑﺔاﻟﻤﻼرﻳﺎ وﺑﻘ
( اﻟﻤﺘﺼﻮرة اﻟﻤﻨﺠﻠﻴﺔ)ﺗﻤﺖ إﺻﺎﺑﺔ اﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء اﻟﺒﺸﺮﻳﺔ ﻓﻲ اﻟﻤﺨﺘﺒﺮ ﺑﺎﻟﻤﺘﺼﻮرة اﻟﻤﻨﺠﻠﻴﺔ : اﻟﻤﻮاد و اﻷﺳﺎﻟﻴﺐ
ﻓﻲ ﻏﻴﺎب و وﺟﻮد اﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب أو اﻟﺰﺑﺪات ، ﺗﻢ ﺗﺤﺪﻳﺪ ﻣﺪى إﻧﺘﺸﺎر اﻟﻤﺘﺼﻮرات ﻓﻲ اﻟﺪم ﺑﺈﺳﺘﺨﺪام ( HniBﺳﻼﻟﺔ )
و ﺗﻢ ﺗﻘﺪﻳﺮ ﺗﺮآﻴﺰ اﻟﻜﺎﻟﺴﻴﻮم ﻓﻲ اﻟﺴﻴﺘﻮﺑﻼزم ﻋﻦ ﻃﺮﻳﻖ ﻗﻴﺎس ﺷﺪة اﻹﺳﺘﻀﺎءة اﻟﻔﻠﻮرﻳﺔ ، أﻣﺎ ﻋﺮض , 61ﺳﺎﻳﺘﻮ 
اﻟﻔﻮﺳﻔﺎﺗﻴﺪﻳﻠﺴﻴﺮﻳﻦ ﻓﻘﺪ ﺗﻢ ﺗﻘﺪﻳﺮﻩ ﻋﻦ ﻃﺮﻳﻖ إرﺗﺒﺎط ﺑﺮوﺗﻴﻦ اﻷﻧﻜﺴﻴﻦ اﻟﺨﺎﻣﺲ و ﺣﺠﻢ اﻟﺨﻠﻴﺔ ﻋﻦ ﻃﺮﻳﻖ اﻟﺒﻌﺜﺮة اﻷﻣﺎﻣﻴﺔ 
اﻟﻔﻴﺌﺮان ﺑﺎﻟﻤﺘﺼﻮرة اﻟﺒﺮﺟﻴﻪ أﻧﻜﺎ ﻋﻦ ﻃﺮﻳﻖ ﺣﻘﻦ ﺗﻤﺖ إﺻﺎﺑﺔ . ﻓﻲ ﻓﺮز اﻟﺘﺤﻠﻴﻠﻲ ﻟﻠﺨﻼﻳﺎ اﻟﻤﻨﺸﻂ ﺑﺎﻹﺿﺎءة اﻟﻔﻠﻮرﻳﺔ
 4.1)ﻓﻲ اﻟﻔﻴﺌﺮان اﻟﻤﺨﺼﺼﺔ ﻟﻠﺪراﺳﺔ اﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ﺗﻢ ﺣﻘﻨﻪ (. 601*  1)اﻟﺘﺠﻮﻳﻒ اﻟﺒﺮﻳﺘﻮﻧﻲ ﺑﺨﻼﻳﺎ ﺣﻤﺮاء ﻣﺼﺎﺑﺔ 
و ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ اﻷﺧﺮى . ﺗﺤﺖ اﻟﺠﻠﺪ ﻣﻦ اﻟﻴﻮم اﻟﺜﺎﻣﻦ ﻣﻦ اﻟﻌﺪوى ﻟﻤﺪة ﺛﻼﺛﺔ أﻳﺎم ﻣﺘﺘﺎﻟﻴﺔ( آﻐﻢ ﻣﻦ وزن اﻟﺠﺴﻢ/ ﻣﻠﻐﻢ 
٪  ﻣﻦ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ اﻟﻤﺬاب ﻓﻲ ﻣﻴﺎﻩ اﻟﺤﻨﻔﻴﺔ اﻋﺘﺒﺎرا ﻣﻦ اﻟﻴﻮم اﻷول ﻣﻦ اﻟﺘﺠﺮﺑﺔ  01اﻟﻔﻴﺌﺮان اﻟﻤﺼﺎﺑﺔ  ﺗﻢ ﺗﻘﺪﻳﻢ ﻣﻦ 
  .ﻣﻊ ﺗﺠﺪﻳﺪ ﻣﺴﺘﺤﻀﺮ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ آﻞ ﻳﻮم ﺧﻼل ﻓﺘﺮة اﻟﻌﻼج
زﻳﺎدة ﻓﻲ  ﻓﻲ اﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء اﻟﺒﺸﺮﻳﺔ ﻓﻲ اﻟﻤﺨﺘﺒﺮ اﻟﻤﺼﺎﺑﺔ ﺑﺎﻟﻤﺘﺼﻮرة اﻟﻤﻨﺠﻠﻴﺔ أدى اﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب إﻟﻰ: اﻟﻨﺘﺎﺋﺞ
ﻋﺮض اﻟﻔﻮﺳﻔﺎﺗﻴﺪﻳﻠﺴﻴﺮﻳﻦ ﻋﻠﻰ ﺳﻄﺢ اﻟﺨﻼﻳﺎ و ﻧﻘﺼﺎن ﻓﻲ اﻟﺘﺒﻌﺜﺮ اﻷﻣﺎﻣﻲ و زﻳﺎدة ﻣﻌﺘﺒﺮة ﻓﻲ ﻧﺸﺎط اﻟﻜﺎﻟﺴﻴﻮم داﺧﻞ 
ﻟﻢ ﻳﺆدي اﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب إﻟﻰ ﺗﻐﻴﻴﺮ ﻣﻌﺘﺒﺮ ﻓﻲ ﻧﺴﺒﺔ اﻷﺣﻤﺎض اﻟﻨﻮوﻳﺔ دﻧﺎ و رﻧﺎ ﻓﻲ داﺧﻞ آﺮﻳﺎت اﻟﺪم . اﻟﺴﻴﺘﻮﺑﻼزم
  . إﻧﺘﺸﺎر اﻟﻄﻔﻴﻞ داﺧﻞ اﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء اﻟﺤﻤﺮاء إﻻ أﻧﻪ أدى إﻟﻰ ﻧﻘﺼﺎن ﻣﻌﺘﺒﺮ ﻓﻲ
اﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء ﻣﻦ اﻟﻔﺌﺮان اﻟﻤﻌﺎﻟﺠﺔ ﺑﺎﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب ﺗﻤﺖ إزاﻟﺘﻬﺎ ﻣﻦ اﻟﺪورة اﻟﺪﻣﻮﻳﺔ ﺑﺴﺮﻋﺔ أآﺒﺮ ﻣﻘﺎرﻧﺔ ﺑﺎﻟﻜﺮﻳﺎت 
و إﺿﺎﻓﺔ إﻟﻰ ذﻟﻚ اﻧﺨﻔﺾ ﻋﺪد اﻟﻜﺮﻳﺎت اﻟﻤﺼﺎﺑﺔ . اﻟﺤﻤﺮاء ﻓﻲ اﻟﻔﺌﺮان اﻟﺘﻲ ﻟﻢ ﺗﺘﻢ ﻣﻌﺎﻟﺠﺘﻬﺎ ﺑﺎﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب
٪ ﻣﻦ اﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء اﻟﻤﻨﺘﺸﺮة  63.93٪ اﻟﻰ  16.05ﻣﻦ )ﺑﺮﺟﻴﻪ ﻓﻲ اﻟﻔﺌﺮان اﻟﻤﺼﺎﺑﺔ ﺑﺸﻜﻞ ﻣﻠﺤﻮظ ﺑﺎﻟﻤﺘﺼﻮرة 
ﻳﻮﻣﺎ ﺑﻌﺪ  72٪  08٪ إﻟﻰ  0ﻣﻦ )آﻤﺎ زادت ﻧﺴﺒﺔ ﺑﻘﺎء اﻟﻔﺌﺮان ﻋﻠﻰ ﻗﻴﺪ اﻟﺤﻴﺎة ﺑﺪرﺟﺔ آﺒﻴﺮة (  ﻳﻮﻣﺎ ﺑﻌﺪ اﻹﺻﺎﺑﺔ 02
 . ﺜﺎﻣﻦ ﻣﻦ اﻟﻌﺪوىﻓﻲ ﺣﺎﻟﺔ ﻣﻌﺎﻟﺠﺘﻬﺎ ﺑﺎﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب ﺗﺤﺖ اﻟﺠﻠﺪ ﻣﻦ اﻟﻴﻮم اﻟ( اﻹﺻﺎﺑﺔ
 X
 
 5.0≤ )ﻓﻲ ﺟﺎﻧﺐ ﺁﺧﺮ ﻣﻦ اﻟﺪراﺳﺔ اﻟﻤﺨﺘﺒﺮﻳﺔ أدت اﻟﺰﺑﺪات اﻟﺘﻲ هﻲ واﺣﺪة ﻣﻦ اهﻢ ﻣﻨﺘﺠﺎت ﺗﺨﻤﻴﺮ اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ 
ﻣﻦ ﻧﺎﺣﻴﺔ أﺧﺮى ﻓﺈﻧﻬﺎ أﺛﺮت ﻋﻠﻰ اﻟﺤﻤﺾ اﻟﻨﻮوي داﺧﻞ . إﻟﻰ إﻧﺨﻔﺎض ﻣﻠﺤﻮظ ﻓﻲ ﺗﻜﺎﺛﺮ اﻟﻤﺘﺼﻮرة اﻟﻤﻨﺠﻠﻴﺔ( ﻣﻠﻢ
آﻤﺎ أدت اﻟﺰﺑﺪات إﻟﻰ زﻳﺎدة . ﻣﻠﻴﻤﻮل 01ﻓﻘﻂ ﻓﻲ ﺗﺮآﻴﺰ / اﻟﺮﻳﺒﻲ اﻟﻜﺮﻳﺎت اﻟﻤﺼﺎﺑﺔ و ذﻟﻚ  ﺑﺘﻀﺨﻴﻢ اﻟﺤﻤﺾ اﻟﻨﻮوي 
آﺒﻴﺮة ﻓﻲ ﻋﺮض اﻟﻔﻮﺳﻔﺎﺗﻴﺪﻳﻠﺴﻴﺮﻳﻦ و اﻧﺨﻔﺎض اﻟﺘﺒﻌﺜﺮ إﻟﻰ اﻷﻣﺎم وإﻟﻰ زﻳﺎدة آﺒﻴﺮة ﻓﻲ ﻧﺸﺎط اﻟﻜﺎﻟﺴﻴﻮم ﻓﻲ 
ﻓﻲ ( ٪ ﻓﻲ ﻣﻴﺎﻩ اﻟﺸﺮب اﻋﺘﺒﺎرا ﻣﻦ اﻟﻴﻮم ﻟﻠﻌﺪوى 01)اﻷهﻢ ﻣﻦ ذﻟﻚ ، أدت اﻟﻤﻌﺎﻟﺠﺔ ﺑﺎﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ . اﻟﺴﻴﺘﻮﺑﻼزم
وزﻳﺎدة ﻓﻲ ﻧﺴﺒﺔ ﺑﻘﺎء اﻟﻔﺌﺮان اﻟﻤﺼﺎﺑﺔ ( 80.85و  93.4±  6.34ﻣﻦ )ﺗﻨﺎﻗﺺ آﺒﻴﺮ ﻓﻲ ﻋﺪد اﻟﺨﻼﻳﺎ اﻟﻤﺼﺎﺑﺔ 
  (.ﻳﻮﻣﺎ ﺑﻌﺪ اﻹﺻﺎﺑﺔ 12٪ ٪  001اﻟﻰ  0ﻣﻦ )ﺑﺎﻟﻤﺘﺼﻮرة ﺑﺮﺟﻴﻪ ﻋﻠﻰ ﻗﻴﺪ اﻟﺤﻴﺎة 
ﺗﺨﻠﺺ هﺬﻩ اﻟﺪراﺳﺔ إﻟﻰ أن اﻻﻣﻔﻮﺗﺮﻳﺴﻴﻦ ب و اﻟﺼﻤﻎ اﻟﻌﺮﺑﻲ ﻳﻘﻮﻣﺎن ﺑﺘﺤﻔﻴﺰ اﻵﻟﻴﺎت اﻟﻤﺴﺆوﻟﺔ ﻋﻦ إﻧﺘﺤﺎر : اﻟﺨﻼﺻﺔ
و هﺬا اﻹزدهﺎر ﻓﻲ إﻧﺘﺤﺎر اﻟﺨﻼﻳﺎ اﻟﺤﻤﺮاء ﻳﺴﺒﻖ ﻧﻀﻮج ﻣﺴﺒﺒﺎت . ﻟﺤﻤﺮاء ﺑﻌﺪ اﻟﻌﺪوى ﻣﻊ اﻟﻤﻨﺠﻠﻴﺔآﺮﻳﺎت اﻟﺪم ا
ﻳﺪاﻓﻊ هﺬا اﻹآﺘﺸﺎف ﻋﻦ أن . ﻟﻤﻀﻴﻒ أﺛﻨﺎء اﻟﻤﻼرﻳﺎاﻟﻤﺮض، وﻳﻤﻨﻊ ﺑﺎﻟﺘﺎﻟﻲ اﻟﻤﺴﺎر اﻟﻘﺎﺗﻞ ﻣﻦ هﺬا اﻟﻤﺮض وﺗﻌﺰز ﺑﻘﺎء ا
اﻟﻨﺘﺎﺋﺞ اﻟﺘﺠﺮﻳﺒﻴﺔ ﺑﺠﺎﻧﺐ أﻧﻬﺎ ﺗﺒﺮر . ﺗﻨﺸﻴﻂ إﻧﺘﺤﺎراﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء اﻟﻤﺼﺎﺑﺔ هﻲ ﺁﻟﻴﺔ ﻳﻌﺘﻤﺪهﺎ اﻟﻤﻀﻴﻒ ﻟﻤﻜﺎﻓﺤﺔ اﻟﻌﺪوى
وﻣﺔ ﻓﻲ إﻧﺘﺤﺎر اﻟﻜﺮﻳﺎت اﻟﺤﻤﺮاء آﺂﻟﻴﺔ ﻟﻠﺤﺪ ﻣﻦ إﻧﺘﺸﺎر اﻟﻤﺮض ﻓﺈﻧﻬﺎ اﻳﻀًﺎ ﺗﻌﺰز ﻧﻬﺠﺎ ﺟﺪﻳﺪا ﻟﻠﺤﻴﻠﻮﻟﺔ دون ﻓﺮص ﻟﻠﻤﻘﺎ
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1. Introduction 
1. 1. Malaria 
Malaria is one of the most prevalent parasitic infections in the world and certainly the most 
detrimental. Each year, over one million people die from the disease, with the vast majority 
of the deaths in children under five years old in Sub-Saharan Africa (1). In addition to the 
overwhelming death toll, over 213 million malarial “attacks” lead to more than 800 million 
days of illness in Africa annually (2, 3) The spread of drug-resistant malaria parasites 
threatens to compound the problem even more. The situation is so dire that economists 
have determined that malaria is a definitive cause of poverty in many afflicted regions (4). 
Furthermore, in malaria-endemic regions, the effect of the disease is also manifested by its 
lasting influence on human genetics, resulting in the preservation of potentially harmful 
variants of human genes (i.e., sickle cell trait), largely because of their advantage in 
heterozygotes protected from severe, complicated, and fatal malaria (1). 
1. 1. 1. History 
The malaria-like intermittent fevers and other symptoms such as enlarged spleen, periods 
of high fever, headaches, shaking chills, and weakness were already known more than 
3000 years ago in Chinese, Assyrian, Indian, and Egyptian manuscripts. Hippocrates (460-
370 B.C.) in Greece is credited with having accurately described the clinical symptoms in 
his medical writings (5). Malaria was widespread in Europe during the middle ages, but 
malaria tropica was endemic only in the warmer South Europe. The name is derived from 
the Italian word mala aria (Latin: malus = bad, aeris = air) because the disease often 
appeared near swamps with their typical odor (6) It was thought that “miasma”, which 
literally means “bad air”, caused the disease (7). The “miasma” theory was proved wrong 
in the 19th century. In 1880 Charles Louis and Alphonse Laveran identified the parasite in 
its blood stage in the act of exflagellation under the microscope (8). In 1897 Sir Ronald 
Ross, whose teacher was Patrick Manson, who discovered the mosquito transmission of 
filariasis, demonstrated the transmission of malaria via mosquitoes (9). However, it was 
only in 1948 that Short and Garnham described the liver stage of primate and human 
malaria Plasmodium vivax (P. vivax) (5). Finally, in 1966 the liver stage of P. falciparum 
was discovered (10). 
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1. 1. 2. Epidemiology of malaria 
The "many epidemiologies" of malaria have been characterized by degrees of endemicity 
(11). Malaria is described as endemic when there is a constant incidence of cases over a 
period of many successive years. At the other extreme malaria transmission may be 
epidemic when there is a periodic or occasional increase in the incidence of cases. A more 
general classification into stable and unstable malaria has been introduced. Stable malaria 
refers to high transmission without any marked fluctuations over years, although seasonal 
fluctuations may exist. Unstable malaria describes transmission that varies from year to 
year with frequent epidemics. The former situation is characterized by high degrees of 
collective immunity whereas the latter is not. These terms describe extremes of a wide 
range of situations (12). 
Malaria is transmitted primarily by the bite of infected female Anopheline mosquitoes. The 
source of infection can be either a sick person or an otherwise asymptomatic carrier of the 
parasite. Malaria can also be transmitted congenitally or by inoculation of infected blood. 
Anophelines feed at night and their breeding sites are primarily in rural areas. The greatest 
risk of malaria infection is therefore from dusk to dawn in rural areas. In many malaria-
endemic areas, there is little or no risk in urban areas. However, urban transmission is 
common in some parts of the world, especially Africa (13, 14). 
The incidence of severe clinical manifestations varies seasonally within endemic areas and 
it is not possible at present to predict which asymptomatic individual will develop severe 
disease (14). The epidemiological profile and clinical pattern of severe malaria in Africa 
has been shown to vary according to the intensity of exposure in persons living in rural 
areas with different levels of transmission (15). The degree of endemicity varies between 
countries and even between different areas in the same country. In Sub-Saharan Africa 
cerebral malaria and severe malarial anaemia are the leading causes of mortality (16). 
The impact of global climate change poses an obvious threat to human health. The insect-
vectors of Plasmodium spp. thrive in warm climates of tropical regions. Global warming 
leading to increased temperature in temperate areas, could provide a habitat suitable for the 
increased distribution of Anopheline vectors. Whether the potential increase in vector 
populations will lead to a concomitant increase in malaria transmission is not clear (17). 
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Malaria is unstable in the semi-arid savannah of central and northern Sudan and the great 
majority of infective bites take place immediately prior to the seasonal peak in number of 
malaria cases in September and October (18). Malaria morbidity and mortality, with 
special reference to central Sudan, affects all age groups (19). In Sudan it has been found 
that, despite variation between districts, urbanization tends to lead to reduced human 
malaria transmission (20). 
1. 1. 3. Clinical manifestations 
The most characteristic symptom of malaria is fever. Other common symptoms include 
chills, headache, myalgia, nausea, and vomiting. Diarrhea, abdominal pain, and cough are 
occasionally seen. As the disease progresses, some patients may develop the classic 
malaria paroxysm with bouts of illness alternating with symptom free periods. The malaria 
paroxysm comprises three successive stages. The first is a 15 to 60 minute cold stage 
characterized by shivering and a feeling of cold. Next, the 2 to 6 hour hot stage, in which 
there is fever, sometimes reaching 41°C, flushed, dry skin, and often headache, nausea, and 
vomiting. Finally, there is the 2 to 4 hour sweating stage during which the fever drops 
rapidly and the patient sweats. In all types of malaria the periodic febrile response is 
caused by rupture of mature schizonts. In P. vivax and P. ovale malaria, a brood of 
schizonts matures every 48 hr, so the periodicity of fever is tertian ("tertian malaria"), 
whereas in P. malariae disease, fever occurs every 72 hours ("quartan malaria"). 
The fever in P. falciparum malaria may occur every 48 hr, but is usually irregular, showing 
no distinct periodicity. These classic fever patterns are usually not seen early in the course 
of malaria, and therefore the absence of periodic, synchronized fevers does not rule out a 
diagnosis of malaria (21). 
A variety of laboratory abnormalities may be seen in a case of uncomplicated malaria. 
These include normochromic, normocytic anemia, thrombocytopenia, leukocytosis or 
leukopenia, hypoglycemia, hyponatremia, elevated liver and renal function tests, 
proteinuria. Patients with complicated malaria may occasionally show evidence of massive 
intravascular hemolysis with hemoglobinemia and hemoglobinuria. 
If the diagnosis of malaria is missed or delayed, especially with P. falciparum infection, 
potentially fatal complicated malaria may develop. The most frequent and serious 
complications of malaria are cerebral malaria and severe anemia. Other complications 
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include: hyperparasitemia (more than 3 to 5% percent of the erythrocytes parasitized); 
severe hypoglycemia; lactic acidosis; shock; pulmonary, cardiac, hepatic, or renal 
dysfunction; seizures; spontaneous bleeding; or massive diarrhea or vomiting. These 
manifestations are usually associated with poor prognosis (21). 
1. 1. 4. The parasites 
There is approximately 400 species of Anopheles throughout the world; about 60 are 
malaria vectors under natural conditions, 30 of which are of major importance. Malaria is 
transmitted by the bite of an infected female Anopheles mosquito. Malaria parasites are 
eukaryotic single-celled microorganisms that belong to the genus Plasmodium. More than 
100 species of Plasmodium can infect various animal species such as reptiles, birds and 
various mammals, but only four species of parasite can infect humans under natural 
conditions: P falciparum, P.vivax, P. ovale and P. malariae. These four species differ in 
their morphology, antigenicity, pathogenicity, drug sensitivity and geographical 
distribution. P.falciparum is species responsible for the severe complications of malaria 
and is the principal cause of malaria deaths in young children in Africa (22, 23). The 
widely worldwide distributed P. vivax is rarely fatal, while P.malariae has a relatively low 
frequency. On the other hand, the least common P. ovale is restricted to West Africa. 
Although both P. falciparum and P.vivax can cause anaemia, mild anaemia is more 
common in P.vivax infections whereas severe anemia is usually caused by P. falciparum.. 
P. ovale and P. vivax have dormant liver stages named hypnozoites that may remain in this 
organ for weeks to many years before the onset of a new round of pre-erythrocytic 
schizogony, resulting in relapses of malaria infection. In some cases P. malariae can 
produce long-lasting blood-stage infections, which, if left untreated, can persist 
asymptomatically in the human host for periods extending into several decades (24). 
1. 1. 5. Life cycle of malaria parasites 
The life cycle of malaria parasites is extremely complex and requires specialized protein 
expression for survival in both the invertebrate and vertebrate hosts. These proteins are 
required for the invasion of a variety of cell types and for the evasion of host immune 
responses. Once injected into the human host, P. falciparum and P. malariae sporozoites 
trigger immediate schizogony, whereas P. ovale and P. vivax sporozoites may either 
trigger immediate schizogony or lead to delayed schizogony as they pass through the 
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hypnozoite stage. The life cycle of the malaria parasite can be divided into several stages 
as shown in figure 1. 1 below, starting with sporozoite entry into the bloodstream (21). 
 
 
Fig. 1. 1. Life cycle of the malaria parasite P. falciparum (24). 
1. 1. 5. 1. Tissue schizogony (pre-erythrocytic schizogony) 
Infective sporozoites from the salivary gland of the Anopheles mosquito are injected into 
the human host along with anticoagulant-containing saliva to ensure an even-flowing blood 
meal. It was thought that sporozoites move rapidly away from the site of injection, but a 
recent study using the rodent parasite (25) species Plasmodium yoelii as a model system 
indicates that, at least in this case, the majority of infective sporozoites remain at the 
injection site for hours, with only slow release into the circulation (26). Once in the human 
bloodstream, P. falciparum sporozoites reach the liver and penetrate the liver cells 
(hepatocytes) where they remain for 9–16 days and undergo asexual replication known as 
exo-erythrocytic schizogony. The mechanism of targeting and invading the hepatocytes is 
not yet well understood, but studies have shown that sporozoite migration through several 
hepatocytes in the mammalian host is essential for completion of the life cycle. Each 
sporozoite gives rise to tens of thousands of merozoites inside the hepatocytes, upon 
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release these merozoites invades red cells to undergo successive waves of schizogeny 
releasing more merozoites to reinvade new red blood cells (RBCs). The time taken to 
complete the liver stage of the parasite life cycle, called the prepatent period, varies, 
depending on the infecting species; (8–25 days for P. falciparum, 8–27 days for P. vivax, 
9–17 days for P. ovale and 15–30 days for P. malariae) (27). 
1. 1. 5. 2. Erythrocytic schizogony 
Merozoites enter erythrocytes by a complex invasion process, which can be divided into 
four phases: (a) initial recognition and reversible attachment of the merozoite to the 
erythrocyte membrane; (b) reorientation and junction formation between the apical end of 
the merozoite (irreversible attachment) and the release of substances from the rhoptry and 
microneme organelles, leading to formation of the parasitophorous vacuole; (c) movement 
of the junction and invagination of the erythrocyte membrane around the merozoite 
accompanied by removal of the merozoite's surface coat; and finally (d) resealing of the 
parasitophorous vacuole and erythrocyte membranes after completion of merozoite 
invasion. Asexual division starts inside the erythrocyte and the parasites develop through 
different stages therein. The early trophozoite is often referred to as the 'ring stage', 
because of its characteristic morphology. Trophozoite enlargement is accompanied by 
highly active metabolism, which includes glycolysis of large amounts of imported glucose, 
the ingestion of host cytoplasm and the proteolysis of hemoglobin into constituent amino 
acids. Malaria parasites cannot degrade the by-product heme which is potentially toxic to 
the parasite. Therefore, during hemoglobin degradation, most of the liberated heme is 
polymerized into hemozoin (malaria pigment), a crystalline substance that is stored within 
the food vacuoles (28). 
The end of this trophic stage is marked by multiple rounds of nuclear division without 
cytokinesis resulting in the formation of schizonts. Each mature schizont contains around 
20 merozoites which are released upon lysis of the RBC to reinvade further uninfected 
RBCs. This release coincides with the sharp increases in body temperature during the 
progression of the disease. This repetitive intraerythrocytic cycle of invasion–
multiplication–release–reinvasion continues, taking about 48 h in P. falciparum, P. ovale 
and P. vivax infections and 72 h in P. malariae infection. It usually occurs quite 
synchronously and the merozoites are released at approximately the same time of the day. 
The contents of the infected RBC that are released upon its lysis stimulate the production 
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of tumour necrosis factor (TNF) and other cytokines, which are responsible for the 
characteristic clinical manifestations of the disease (24). 
A small proportion of the merozoites in the RBCs eventually differentiate to produce 
micro- and macrogametocytes (male and female, respectively), which have no further 
activity within the human host. These gametocytes are essential for transmitting the 
infection to new hosts after undergoing an sporogenic cycle in female Anopheles 
mosquitoes. Normally, variable numbers of cycles of asexual erythrocytic schizogony 
occur before any gametocytes are produced. In P. falciparum, erythrocytic schizogony 
takes 48 h and gametocytogenesis takes 10–12 days. Gametocytes appear on the fifth day 
of primary attack in P. vivax and P. ovale infections, and thereafter become more 
numerous; they appear at anything from 5 to 23 days after a primary attack by P. malariae 
(24). 
1. 1. 5. 3. Sexual phase in the mosquito (Sporogony) 
A mosquito taking a blood meal on an infected individual may ingest these gametocytes 
into its midgut, where macrogametocytes form macrogametes and exflagellation of 
microgametocytes produces microgametes. These gametes fuse, undergo fertilization and 
form a zygote. This transforms into an ookinete, which penetrates the wall of a cell in the 
midgut and develops into an oocyst. In a recent study (29), it has been shown that gamete 
surface antigen Pfs230 mediates human RBC binding to exflagellating male parasites to 
form clusters termed exflagellation centers, from which individual motile microgametes 
are released. This protein thus plays an important role in subsequent oocyst development, 
which is a critical step in malaria transmission. Sporogony within the oocyst produces 
many sporozoites and when the oocyst ruptures, they migrate to the salivary glands for 
onward transmission into another vertebrate host. This infective “sporozoite” form of the 
parasite reaches the salivary glands after 10–18 days and thereafter the mosquito becomes 
infective for 1–2 months (30). 
1. 1. 6. Malaria immunity 
There are different types of protective immunity against malaria, one type is the clinical 
immunity which reduces the intensity of clinical symptoms and the risk of death from 
malaria, the other type is the antiparasitic immunity which directly reduces the number of 
parasites in the infected individual (31). In the case of P .falciparum malaria, it is possible 
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that a certain degree of immunity to some aspects of severe disease may be attained after 
only one or two infections (32). However, effective antiparasitic immunity is only attained 
after several frequent infections (33). 
1. 1. 6. 1. Innate immunity 
Some individuals are either naturally resistant to malaria infection or less likely to develop 
a severe form of the disease. Innate resistance to infection is generally only a partial 
resistance, and may be linked to the fact that malaria parasites find it harder to invade 
certain types of human erythrocytes. Also, it could be due to the fact that certain host 
erythrocytes have a reduced ability to sustain the growth of parasites (33). 
1. 1. 6. 2. Acquired immunity 
In endemic areas, most adults have a degree of immunity that controls parasite replication 
but not sterile immunity which eliminates parasite from blood. Acquired immunity to 
malaria develops after repeated exposure to the parasite (34). 
1. 1. 6. 3. Strain specific immunity 
The long time required to develop protective immunity against malaria may be explained 
by poor immunogenicity of the parasite and/or that immune responses are strain specific. A 
large number of infections would then be required to encounter the whole local repertoire 
of different antigens. Early studies of induced malaria indicated that malaria immunity is 
strain specific (35, 36). 
1. 1. 7. Malaria diagnosis 
The standard method for detection of Plasmodium in human blood is by microscopical 
examination of Romanovsky-stained thick and thin blood films. This technique can, when 
used in optimal conditions by a competent microscopist, detect a parasitaemia as low as 
0.001% (10-40 parasites per µl of blood), but it is a time-consuming technique for the 
detection of scanty parasites and often difficult to use accurately to identify mixed 
infections. Several alternative diagnostic methods have been developed in order to reduce 
the time spent examining slides or to enable fairly competent personnel to achieve equally 
reliable results. These include: 
Antigen detection: Various test kits are available to detect antigens derived from malaria 
parasites. Such immunochromatographic tests most often use a dipstick or cassette format, 
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and provide results in 2-15 minutes. These "Rapid Diagnostic Tests" (RDTs) offer a useful 
alternative to microscopy in situations where reliable microscopic diagnosis is not 
available. Malaria RDTs are currently used in some clinical settings and programs. 
However, before malaria RDTs can be widely adopted, several issues remain to be 
addressed, including improving their accuracy; lowering their cost; and ensuring their 
adequate performance under adverse field conditions (37). 
Molecular diagnosis: Parasite nucleic acids are detected using polymerase chain reaction 
(PCR). This technique is more accurate than microscopy. However, it is expensive, and 
requires a specialized laboratory even though technical advances will likely result in field-
operated PCR machines (37). 
Serology: Serology detects antibodies against malaria parasites, using either indirect 
immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). Serology 
does not detect current infection but rather measures past experience (37). 
1. 1. 8. Malaria chemotherapy 
Chemotherapy is important in alleviating the suffering and reducing the mortality caused 
by the disease. The action of antimalarial drugs ties in their effect on the metabolic process 
or the vital structure of the parasite which lead to the disruption of its activity and then to 
parasite death. However the efficacy of the drug depends also on the species and strain of 
the parasite and its sensitivity towards a given drug, as well as the state of host immunity 
(38). 
Patients successfully treated with antimalarial drugs may thus be healthy but may remain 
infective for up to two months until the P. falciparum gametocytes die off naturally, or 
until another drug such as primaquine is given to eliminate the mature gametocytes (39). 
1. 1. 8. 1. 4, 8-aminoquinoline drugs 
Such as chloroquine, amodiaquine, and primaquine. Chloroquine is a 4-aminoquinoline 
that has marked and rapid schizonticidal activity against all infections of P. malariae and 
P. ovale and against chloroquine-sensitive infections of P. falciparum and P. vivax. It is 
also gametocytocidal against P. vivax, P, malariae and P. ovale as well as immature 
gametocytes of P. falciparum. It is not active against hepatic stages, and should therefore 
be used with primaquine to effect radical cure of P. vivax and P. ovale. It was the most 
important antimalarial for more than 40 years because of its activity against the four 
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plasmodia that infect human (39). In addition, chloroquine is known to be safe for children 
and pregnant women (38, 40). However, the efficacy of chloroquine has been severely 
compromised by the spread of chloroquine-resistant strains of P. falciparum, which are 
now prevalent in Southeast Asia, South and Central America, and sub-Saharan Africa (41) 
where drug-resistance led to increased morbidity and mortality of malaria  and forced the 
use of alternative drugs (42). 
1. 1. 8. 2. Antifolate drugs 
The only useful combinations of antifolate drugs for the treatment of malaria are 
synergistic mixtures that act against the parasite-specific enzymes, dihydropteroate 
synthetase and dihydrofolate reductase. Available combinations include the sulfa and 
pyrimethamine combinations sulfadoxine-pyrimethamine and sulfalene-pyrimethamine, 
the former being more widely available (43). 
Antifolate drugs such as pyrimethamine and proguanil are slow blood schizonticides but 
they have the advantage that they are effective in smaller doses, safe and free from side 
effects. The ability of sulfa (sulfonamides and sulfones) to show potentiating effect with 
proguanil or pyrimethamine (44) suggested that combination of these two groups of drugs 
would not only be more effective antimalarial agent, but would also delay, if not avoid, the 
development of resistance. The most commonly used combination is that of sulfonamide, 
sulfadoxine, and pyrimethamine (fansidar), which has been particularly effective in areas 
such as Africa where chloroquine resistance is now wide spreading (45). However, 
resistance to the pyrimethamine sulfadoxine combination became widespread and the 
successive failure of these two drugs in Africa was described in 1998 as malaria disaster 
(45). 
1. 1. 8. 3. Quinine 
It is normally effective against P.falciparum infections that are resistant to chloroquine and 
sulfa drug-pyrimethamine combinations. Decreasing sensitivity to quinine has been 
detected in areas of South-East Asia where it has been extensively used for malaria 
therapy. This has occurred particularly when therapy was given in an unsupervised and 
ambulatory setting with regimens longer than 3 days. In these settings, patient adherence to 
therapy is low, leading to incomplete treatment; this may have led to the selection of 
resistant parasites (46). 
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1. 1. 8. 4. Artemisinin and its derivatives 
Artemisinin is poorly soluble in oils or water but the parent compound has yielded 
dihydroartemisinin, the oil-soluble derivatives artemether and arteether, and the more 
water-soluble derivatives sodium artesunate and artetinic acid. These derivatives have 
more potent blood schizonticidal activity than the parent compound and are the most 
rapidly effective antimalarial drugs known. They are used for the treatment of severe and 
uncomplicated malaria (47). They are not hypnozoiticidal but gametocytocidal activity has 
been observed. These compounds are not recommended for use in the treatment of malaria 
due to P. vivax, P. malariae or P. ovale since other effective antimalarial drugs are 
available for this purpose (39). 
1. 1. 8. 5. Combination therapy to combat the spread of drug resistance 
Due to the emergence and rapid spread of resistance to almost all available antimalarial 
drugs, much of interest has been focused upon the use of drugs in combination. The 
underlying science behind the therapeutic effect of the combinations that include an 
artemisinin derivative is that the artemisinin rapidly kills most of the parasites and then 
those that remain are killed by the companion drug (39). 
Combination therapy (CT) is defined as "the simultaneous use of two or more antimalarial 
drugs with different biochemical targets in the parasite or in tissue hosting the parasite, 
which are synergistic, additive or complementary in their effect". Using this definition, two 
or more drugs which have the same biochemical target in the parasite such as sulfadoxine, 
and pyrimethamine, chlorproguanil-dapsone, atovaquone-proguanil are not considered CT. 
Similarly, an antimalarial which is co-administered with a non-antimalarial drug which 
enhances its action is also not classified as CT. Suffice to say that CT therefore can be 
either fixed combinations, where all components are coformulated in a single 
tablet/capsule or free combinations where the components are in separate tablets/capsules 
but are coadministered (39). 
In sub-Saharan Africa, the first two combinations considered in a larger scale were 
pyrimethamine/sulfadoxine plus chloroquine and pyrimethamine/sulfadoxine plus 
amodiaquine (39). Recently interest has been directed towards the use of drugs in 
combination with artesunate in purpose of delaying the emergence of resistance (48). The 
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antifolate product proguanil has been formulated together with a new type of inhibitor, 
atovaquone, to yield malar-one, recently licensed for clinical use (49). 
1. 2. Apoptosis 
Apoptosis is the process of programmed cell death (PCD), that may occurs normally 
during development and aging as a homeostatic mechanism to maintain cell populations in 
tissues. Apoptosis also occurs as a defence mechanism such as in immune reactions or 
when cells are damaged by disease or noxious agents. Although there are a wide variety of 
stimuli and conditions, both physiological and pathological, that can trigger apoptosis, not 
all cells will necessarily die in response to the same stimulus. Irradiation or drugs used for 
cancer chemotherapy results in DNA damage in some cells, which can lead to apoptotic 
death through a p53-dependent pathway. Some hormones, such as corticosteroids, may 
lead to apoptotic death in some cells (e.g., thymocytes) although other cells are unaffected 
or even stimulated. Apoptosis is a coordinated and often energy-dependent process that 
involves the activation of a group of cysteine proteases called “caspases” and a complex 
cascade of events that link the initiating stimuli to the final demise of the cell (50). 
1. 2. 1. Morphology of apoptosis 
Light and electron microscopy have identified the various morphological changes that 
occur during apoptosis (51). During the early process of apoptosis, cell shrinkage and 
pyknosis are visible by light microscopy (52). With cell shrinkage, the cells are smaller in 
size, the cytoplasm is dense and the organelles are more tightly packed. Pyknosis is the 
result of chromatin condensation and this is the most characteristic feature of apoptosis. On 
histological examination with hematoxylin and eosin stain, the apoptotic cell appears as a 
round or oval mass with dark eosinophilic cytoplasm and dense purple nuclear chromatin 
fragments. Early during the chromatin condensation phase, the electron-dense nuclear 
material characteristically aggregates peripherally under the nuclear membrane although 
there can also be uniformly dense nuclei. Blebbing which is an extensive irregular bulging 
of the plasma membrane detached from the cytoskeleton occurs followed by karyorrhexis 
and separation of cell fragments into apoptotic bodies during a process called “budding.” 
Apoptotic bodies consist of cytoplasm with tightly packed organelles with or without a 
nuclear fragment. The organelle integrity is still maintained and all of this is enclosed 
within an intact plasma membrane. These bodies are subsequently phagocytosed by 
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macrophages, parenchymal cells, or neoplastic cells and degraded within phagolysosomes. 
Macrophages that engulf and digest apoptotic cells are called “tingible body macrophages” 
and are frequently found within the reactive germinal centers of lymphoid follicles or 
occasionally within the thymic cortex. The tingible bodies are the bits of nuclear debris 
from the apoptotic cells. There is essentially no inflammatory reaction associated neither 
with the process of apoptosis nor with the removal of apoptotic cells because: (1) apoptotic 
cells do not release their cellular constituents into the surrounding interstitial tissue; (2) 
they are quickly phagocytosed by surrounding cells thus likely preventing secondary 
necrosis; and, (3) the engulfing cells do not produce anti-inflammatory cytokines (53, 54). 
1. 2. 2. Classification of cell death: apoptosis and necrosis 
Mechanisms of cell death varies with cell type, developmental stage, metabolism and the 
kind of death signal. Apoptosis is a major form of programmed cell death, although there 
are still other types of programmed cell death, especially in pathological situations 
(autophagic death, cytoplasmic death, parapoptosis etc.). These modes of cell death are, 
however, much less studied (55, 56). 
The alternative to apoptotic cell death is necrosis, which is considered to be a toxic process 
where the cell is a passive victim and follows an energy-independent mode of death. But 
since necrosis refers to the degradative processes that occur after cell death, it is considered 
to be an inappropriate term to describe a mechanism of cell death. Oncosis is therefore 
used to describe a process that leads to necrosis with karyolysis and cell swelling whereas 
apoptosis describes the process that involves cell shrinkage, pyknosis, and karyorrhexis. 
Necrosis is an uncontrolled and passive process that usually affects large fields of cells 
whereas apoptosis is controlled and energy-dependent and can affect individual or clusters 
of cells. Necrotic cell injury is mediated by two main mechanisms; interference with the 
energy supply of the cell and direct damage to cell membranes (57). 
Although the mechanisms and morphologies of apoptosis and necrosis differ, there is 
overlap between these two processes. Evidence indicates that necrosis and apoptosis 
represent morphologic expressions of a shared biochemical network described as the 
“apoptosis-necrosis continuum” (58). For example, two factors that convert an ongoing 
apoptotic process into a necrotic process include a decrease in the availability of caspases 
and intracellular ATP (58, 59). It is not always easy to distinguish apoptosis from necrosis 
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by conventional histological examinations. Both processes can occur simultaneously 
depending on factors such as the intensity and duration of the stimulus, the extent of ATP 
depletion and the availability of caspases (58). 
Some of the major morphological changes that occur with necrosis include cell swelling; 
formation of cytoplasmic vacuoles; distended endoplasmic reticulum; formation of 
cytoplasmic blebs; condensed, swollen or ruptured mitochondria; disaggregation and 
detachment of ribosomes; disrupted organelle membranes; swollen and ruptured 
lysosomes; and eventually disruption of the cell membrane (52, 57, 60). This loss of cell 
membrane integrity results in the release of the cytoplasmic contents into the surrounding 
tissue, sending chemotatic signals with eventual recruitment of inflammatory cells. 
Because apoptotic cells do not release their cellular constituents into the surrounding 
interstitial tissue and are quickly phagocytosed by macrophages or adjacent normal cells, 
there is essentially no inflammatory reaction (53, 54). It is also important to note that 
pyknosis and karyorrhexis are not exclusive to apoptosis and can be a part of the spectrum 
of cytomorphological changes that occurs with necrosis (58). 
1. 2. 3. Mechanisms of apoptosis 
The mechanisms of apoptosis are highly complex and sophisticated, involving an energy-
dependent cascade of molecular events (Figure 1. 2). To date, research indicates that there 
are two main apoptotic pathways: the extrinsic or death receptor pathway and the intrinsic 
or mitochondrial pathway. However, there is now evidence that the two pathways are 
linked and that molecules in one pathway can influence the other (61). There is an 
additional pathway that involves T-cell mediated cytotoxicity and perforin-granzyme-
dependent killing of the cell. The perforin/granzyme pathway can induce apoptosis via 
either granzyme B or granzyme A. The extrinsic, intrinsic, and granzyme B pathways 
converge on the same terminal, or execution pathway. This pathway is initiated by the 
cleavage of caspase-3 and results in DNA fragmentation, degradation of cytoskeletal and 
nuclear proteins, cross-linking of proteins, formation of apoptotic bodies, expression of 
ligands for phagocytic cell receptors and finally uptake by phagocytic cells. The granzyme 
A pathway activates a parallel, caspase-independent cell death pathway via single stranded 
DNA damage (62). 
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1. 2. 4. Biochemical features of apoptosis 
Apoptotic cells exhibit several biochemical changes such as protein cleavage, protein 
cross-linking, DNA breakdown, and phagocytic recognition that together result in the 
distinctive structural pathology. Cysteine-aspartic proteases (Caspases) are widely 
expressed in an inactive proenzyme form in most cells and once activated can often 
activate other procaspases, allowing initiation of a protease cascade. Some procaspases can 
also aggregate and autoactivate. This proteolytic cascade, in which one caspase can 
activate other caspases, amplifies the apoptotic signalling pathway and thus leads to rapid 
cell death (63). 
Caspases have proteolytic activity and are able to cleave proteins at aspartic acid residues, 
although different caspases have different specificities involving recognition of 
neighbouring amino acids. Once caspases are initially activated, there seems to be an 
irreversible commitment towards cell death. Fourteen major caspases have been identified 
and were broadly categorized into initiators (caspase-2,-8,-9,-10), effectors or executioners 
(caspase-3,-6,-7) and inflammatory caspases (caspase-1,-4,-5) (64, 65). The other caspases 
that have been identified include caspase-11 which regulates apoptosis and cytokine 
secretion during septic shock, caspase-12 which mediates endoplasmic-specific apoptosis 
and cytotoxicity by amyloid-β, caspase-13 which is suggested to be a bovine gene and 
caspase-14 which is highly expressed in embryonic tissues but not in adult tissues (66-68). 
Extensive protein cross-linking is another characteristic of apoptotic cells and is achieved 
through the expression and activation of tissue transglutaminase (69). DNA breakdown by 
Ca2+-and Mg2+-dependent endonucleases also occurs, resulting in DNA fragments of 180 
to 200 base pairs. A characteristic “DNA ladder” can be visualized by agarose gel 
electrophoresis with an ethidium bromide stain and ultraviolet illumination (70). 
Another biochemical feature is the expression of cell surface markers that result in the 
early phagocytic recognition of apoptotic cells by adjacent cells, permitting quick 
phagocytosis with minimal compromise to the surrounding tissue. This is achieved by the 
movement of the normal inward-facing phosphatidylserine of the cell’s lipid bilayer to 
expression on the outer layers of the plasma membrane (71). Although externalization of 
phosphatidylserine is a well-known recognition ligand for phagocytes on the surface of the 
apoptotic cell, other proteins are also being exposed on the cell surface during apoptotic 
16 
 
cell clearance. These include Annexin I and calreticulin. Calreticulin is a protein that binds 
to an LDL-receptor related protein on the engulfing cell and is suggested to cooperate with 
phosphatidylserine as a recognition signal (72). Annexin V is a recombinant 
phosphatidylserine-binding protein that interacts strongly and specifically with 
phosphatidylserine residues and can be used for the detection of apoptosis (73). 
1. 2. 4. 1. Extrinsic pathway of apoptosis 
The extrinsic signalling pathways that initiate apoptosis involve trans-membrane receptor-
mediated interactions. These involve death-receptors that are members of the tumour 
necrosis factor (TNF) receptor gene superfamily (74). Members of the TNF receptor 
family share similar cyteine-rich extracellular domains and have a cytoplasmic domain of 
about 80 amino acids called the “death domain” (75). This death domain plays a critical 
role in transmitting the death signal from the cell surface to the intracellular signalling 
pathways. To date, the best-characterized ligands and corresponding death receptors 
include fatty acid synthase ligand/ fatty acid synthase receptors (FasL/FasR), tumor 
necrosis factor-α/ tumor necrosis factor receptor (TNF-α/TNFR1), apoptosis 3 ligand/death 
receptors 3 (Apo3L/DR3), and apoptosis 2 ligand/death receptors 4 (Apo2L/DR4) (76-78). 
The sequences of events that define the extrinsic phase of apoptosis are best characterized 
with the FasL/FasR and TNF-α/TNFR1 models. In these models, there is clustering of 
receptors and binding with the homologous trimeric ligand. Upon ligand binding, 
cytplasmic adapter proteins are recruited which exhibit corresponding death domains that 
bind with the receptors. The binding of Fas ligand to Fas receptor results in the binding of 
the adapter protein, Fas-associated death domain (FADD) and the binding of TNF ligand to 
TNF receptor results in the binding of the adapter protein TNFReceptor-associated death 
domain (TRADD) with recruitment of FADD and receptor-interacting protein (RIP) (79). 
FADD then associates with procaspase-8 via dimerization of the death effector domain. At 
this point, a death-inducing signalling complex (DISC) is formed, resulting in the auto-
catalytic activation of procaspase-8 (80). Once caspase-8 is activated, the execution phase 
of apoptosis is triggered (76). 
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Fig. 1. 2: Schematic representation of apoptotic events. The two main pathways of apoptosis are extrinsic 
and intrinsic as well as a perforin/granzyme pathway. Each requires specific triggering signals to begin an 
energy-dependent cascade of molecular events. Each pathway activates its own initiator caspase (8, 9, 10) 
which in turn will activate the executioner caspase-3. However, granzyme A works in a caspase-independent 
fashion. The execution pathway results in characteristic cytomorphological features including cell shrinkage, 
chromatin condensation, formation of cytoplasmic blebs and apoptotic bodies and finally phagocytosis of the 
apoptotic bodies by adjacent parenchymal cells, neoplastic cells or macrophages (69). 
 
 
1. 2. 4. 2. Perforin/granzyme pathway of apoptosis 
T-cell are able to exert their cytotoxic effects on tumour cells and virus-infected cells via a 
novel pathway that involves secretion of the trans-membrane pore-forming molecule 
perforin with a subsequent exophytic release of cytoplasmic granules through the pore and 
into the target cell (79). The serine proteases granzyme A and granzyme B are the most 
important component within the granules (80). Granzyme B will cleave proteins at 
aspartate residues and will therefore activate procaspase-10 and can cleave factors like 
ICAD (Inhibitor of Caspase Activated DNAse) (81). Granzyme B also can utilize the 
mitochondrial pathway for amplification of the death signal by specific cleavage of Bid 
and induction of cytochrome c release (82). 
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Granzyme A is also important in cytotoxic T cell induced apoptosis and it activates caspase 
independent pathways. Once in the cell, granzyme A activates DNA nicking through 
DNAse NM23-H1, a tumor suppressor gene product (83). This DNAse has an important 
role in immune surveillance to prevent cancer through the induction of tumor cell 
apoptosis. The nucleosome assembly protein SET normally inhibits the NM23-H1 gene. 
Granzyme A protease cleaves the SET complex thus releasing inhibition of NM23-H1, 
resulting in apoptotic DNA degradation. In addition to inhibiting NM23-H1, the SET 
complex has important functions in chromatin structure and DNA repair. The proteins that 
make up this complex (SET, Ape1, pp32, and HMG2) seem to work together to protect 
chromatin and DNA structure. Therefore, inactivation of this complex by granzyme A is 
likely to contribute to apoptosis by blocking the maintenance of DNA and chromatin 
structure integrity (84). 
1. 2. 4. 3. Intrinsic pathway of apoptosis 
The intrinsic signalling pathway of apoptosis involves a diverse array of non-receptor-
mediated stimuli that produce intracellular signals which act directly on targets within the 
cell and are mitochondrial-initiated events. The stimuli that initiate the intrinsic pathway 
produce intracellular signals that may act in either a positive or negative fashion. Negative 
signals involve the absence of certain growth factors, hormones and cytokines that can lead 
to failure of suppression of death programs, thereby triggering apoptosis. In other words, 
there is the withdrawal of factors, loss of apoptotic suppression, and subsequent activation 
of apoptosis. Other stimuli that act in a positive fashion include, but are not limited to, 
radiation, toxins, hypoxia, hyperthermia, viral infections, and free radicals (87). 
All apoptotic stimuli cause changes in the inner mitochondrial membrane and result in an 
opening of the mitochondrial permeability transition (MPT) pore, loss of the mitochondrial 
trans-membrane potential and release of two main groups of normally sequestered pro-
apoptotic proteins from the intermembrane space into the cytosol (87). The first group 
consists of cytochrome c, Second Mitochondria-derived Activator of Caspases/Direct IAP 
Binding Protein with Low PI (Smac/DIABLO), and the serine protease HtrA2/Omi (88). 
These proteins activate the caspase-dependent mitochondrial pathway. Cytochrome c binds 
and activates Apaf-1 as well as procaspase-9, forming an “apoptosome” (89, 90). The 
second group of pro-apoptotic proteins, include the apoptosis-inducing factor (AIF), 
endonuclease G and caspase-activated Dnase (CAD) are released from the mitochondria 
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during apoptosis, but this is a late event that occurs after the cell has been committed to 
death. AIF translocates to the nucleus and causes DNA fragmentation into ~50–300 kb 
pieces and condensation of peripheral nuclear chromatin (91). 
The control and regulation of these apoptotic mitochondrial events occurs through 
members of the B-cell lymphoma 2 (Bcl-2) family of proteins (92). The tumour suppressor 
protein p53 has a critical role in regulation of the Bcl-2 family of proteins; however the 
exact mechanisms have not yet been completely elucidated. The Bcl-2 family of proteins 
governs mitochondrial membrane permeability and can be either pro-apoptotic or anti-
apoptotic. It is thought that the main mechanism of action of the Bcl-2 family of proteins is 
the regulation of cytochrome c release from the mitochondria via alteration of 
mitochondrial membrane permeability (93). 
1. 2. 4. 4. Execution pathway of apoptosis 
The extrinsic and intrinsic pathways both end at the point of the execution phase which is 
the final pathway of apoptosis. It is the activation of the execution caspases that triggers 
this phase of apoptosis. Execution caspases activate cytoplasmic endonuclease, which 
degrades nuclear material, and proteases that degrade the nuclear and cytoskeletal proteins. 
Caspase-3, 6 and 7 act as effectors or “executioner” caspases, cleaving various substrates 
including cytokeratins, Poly (ADP-ribose) polymerase (PARP), the plasma membrane 
cytoskeletal protein alpha fodrin, the nuclear mitotic apparatus protein (NuMA) and others, 
that ultimately cause the morphological and biochemical changes seen in apoptotic cells 
(94). 
1. 2. 5. Physiologic apoptosis 
The role of apoptosis in normal physiology is as significant as that of its counterpart, 
mitosis. It demonstrates a complementary but opposite role to mitosis and cell proliferation 
in the regulation of various cell populations. It is estimated that to maintain homeostasis in 
the adult human body, around 10 billion cells are made each day just to balance those 
dying by apoptosis. And that number can increase significantly when there is increased 
apoptosis during normal development and aging or during disease (95). 
Apoptosis is critically important during various developmental processes. Apoptosis is 
necessary to rid the body of pathogen-invaded cells and is a vital component of wound 
healing in that it is involved in the removal of inflammatory cells and the evolution of 
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granulation tissue into scar tissue (96). Additionally, apoptosis is central to remodelling in 
the adult, such as the follicular atresia of the postovulatory follicle and post-weaning 
mammary gland involution (97, 98). Furthermore, as organisms grow older, some cells 
begin to deteriorate at a faster rate and are eliminated via apoptosis. It is clear that 
apoptosis has to be tightly regulated since too little or too much cell death may lead to 
pathology, including developmental defects, autoimmune diseases, neurodegeneration or 
cancer (99, 100). 
1. 2. 6. Pathologic apoptosis 
Abnormalities in cell death regulation can be a significant component of diseases such as 
cancer, autoimmune lymphoproliferative syndrome, acquired immune deficiency 
syndrome (AIDS), ischemia, and neurode-generative diseases such as Parkinson’s disease, 
Alzheimer’s disease, Huntington’s disease, and Amyotrophic Lateral Sclerosis. Some 
conditions feature insufficient apoptosis whereas others feature excessive apoptosis. 
Cancer is an example where the normal mechanisms of cell cycle regulation are 
dysfunctional, with either an over-proliferation of cells and/or decreased removal of cells 
(95, 101). 
Excessive apoptosis may also be a feature of some conditions such as autoimmune 
diseases, neurodegenerative diseases, and ischemia-associated injury. Acquired immune 
deficiency syndrome (AIDS) is an example of an autoimmune disease that results from 
infection with the human immunodeficiency virus (HIV) (102). 
1. 2. 7. Inhibition of apoptosis 
There are many pathological conditions that exhibit excessive apoptosis 
(neurodegenerative diseases, AIDS, ischemia, etc.) and thus may benefit from artificially 
inhibiting apoptosis. However, understanding of the field evolves, the identification and 
exploitation of new targets remains a considerable focus of attention (103). A short list of 
potential methods of anti-apoptotic therapy includes stimulation of the inhibitors of 
apoptosis proteins (IAP) family of proteins, caspase inhibition, PARP (poly [ADP-ribose] 
polymerase) inhibition, stimulation of the protein kinase B (PKB) pathway, and inhibition 
of Bcl-2 proteins. The inhibitor of apoptosis (IAP) family of proteins is perhaps the most 
important regulators of apoptosis due to the fact that they regulate both the intrinsic and 
extrinsic pathways (104). 
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1. 2. 8. Assays for apoptosis 
Since apoptosis occurs via a complex signalling cascade that is tightly regulated at multiple 
points, there are many opportunities to evaluate the activity of the proteins involved. As the 
activators, effectors and regulators of this cascade continue to be elucidated, a large 
number of apoptosis assays are devised to detect and count apoptotic cells. However, many 
features of apoptosis and necrosis can overlap, and it is therefore crucial to employ two or 
more distinct assays to confirm that cell death is occurring via apoptosis. One assay may 
detect early (initiation) apoptotic events and a different assay may target a later (execution) 
event. The second assay, used to confirm apoptosis, is generally based on a different 
principle. Multiplexing, which is the ability to gather more than one set of data from the 
same sample, is another methodology for apoptosis detection that is becoming increasingly 
popular. There are a large variety of assays available, but each assay has advantages and 
disadvantages which may make it acceptable to use for one application but inappropriate 
for another application (105, 106). Therefore, when choosing methods of apoptosis 
detection in cells, tissues or organs, understanding the pros and cons of each assay is 
crucial. However, apoptosis assays can be classified into six major groups:  
1. Cytomorphological alterations 
2. DNA fragmentation 
3. Detection of caspases, cleaved substrates, regulators and inhibitors 
4. Membrane alterations 
5. Detection of apoptosis in whole mounts  
6. Mitochondrial assays. 
1. 2. 8. 1. Cytomorphological alterations  
The evaluation of hematoxylin and eosin-stained tissue sections with light microscopy 
does allow the visualization of apoptotic cells. Although a single apoptotic cell can be 
detected with this method, confirmation with other methods may be necessary. Because the 
morphological events of apoptosis are rapid and the fragments are quickly phagocytosed, 
considerable apoptosis may occur in some tissues before it is histologically apparent. 
Additionally, this method detects the later events of apoptosis, so cells in the early phase of 
apoptosis will not be detected (107). 
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1. 2. 8. 2. DNA fragmentation 
The DNA laddering technique is used to visualize the endonuclease cleavage products of 
apoptosis. This assay involves extraction of DNA from a lysed cell homogenate followed 
by agarose gel electrophoresis. The assay results in a characteristic “DNA ladder” with 
each band in the ladder separated in size by approximately 180 base pairs. This method is 
easy to perform, has a sensitivity of 1 × 106 cells (i.e., level of detection is as few as 
1,000,000 cells), and is useful for tissues and cell cultures with high numbers of apoptotic 
cells per tissue mass or volume, respectively. On the other hand, it is not recommended in 
cases with low numbers of apoptotic cells. There are other disadvantages to this assay. 
Since DNA fragmentation occurs in the later phase of apoptosis, the absence of a DNA 
ladder does not eliminate the potential that cells are undergoing early apoptosis. 
Additionally, DNA fragmentation can occur during preparation making it difficult to 
produce a nucleosome ladder and necrotic cells can also generate DNA fragments (107). 
1. 2. 8. 3. Membrane alterations 
Externalization of phosphatidylserine residues on the outer plasma membrane of apoptotic 
cells allows detection via Annexin V in tissues, embryos or cultured cells. Once the 
apoptotic cells are bound with fluorescein isothiocyanate (FITC)-labeled Annexin V, they 
can be visualized with fluorescent microscopy. The advantages are sensitivity (can detect a 
single apoptotic cell) and the ability to confirm the activity of initiator caspases. The 
disadvantage is that the membranes of necrotic cells are labelled as well (108). 
1. 2. 8. 4. Detection of apoptosis in whole mounts 
Apoptosis can also be visualized in whole mounts of embryos or tissues using dyes such as 
acridine orange (AO), Nile blue sulphate (NBS), and neutral red (NR). Since these dyes are 
acidophilic, they are concentrated in areas of high lysosomal and phagocytotic activity. 
The results would need to be validated with other apoptosis assays because these dyes 
cannot distinguish between lysosomes degrading apoptotic debris from degradation of 
other debris such as microorganisms. Although all of these dyes are fast and inexpensive, 
they have certain disadvantages. AO is toxic and mutagenic and quenches rapidly under 
standard conditions whereas NBS and NR do not penetrate thick tissues and can be lost 
during preparation for sectioning (109). 
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1. 2. 8. 5. Mitochondrial assays 
Mitochondrial assays and cytochrome c release allow the detection of changes in the early 
phase of the intrinsic pathway. Laser scanning confocal microscopy (LSCM) creates 
submicron thin optical slices through living cells that can be used to monitor several 
mitochondrial events in intact single cells over time (110). Mitochondrial permeability 
transition (MPT), depolarization of the inner mitochondrial membrane, Ca2+ fluxes, 
mitochondrial redox status, and reactive oxygen species can all be monitored with this 
methodology. The main disadvantage is that the mitochondrial parameters that this 
methodology monitors can also occur during necrosis. The electrochemical gradient across 
the mitochondrial outer membrane (MOM) collapses during apoptosis, allowing detection 
with a fluorescent cationic dye (69). 
1. 3. Erythrocyte suicidal death (Erypyosis)  
Erythrocytes are devoid of nuclei and mitochondria and thus lack crucial elements in the 
machinery of apoptosis. However, similar to other cell types, erythrocytes have to be 
eliminated when they are defective or after their physiological life span of 120 days (111) 
in case of human beings. Due to the lack of key organelles involved in the process of 
apoptosis it was considered that erythrocytes are unable to undergo apoptosis and hence 
have to be eliminated by mechanisms other than apoptosis. It has been observed that 
erythrocyte senescence is associated with cell shrinkage, plasma membrane 
microvesiculation, a progressive shape change from a discocyte to a spherocyte, 
cytoskeleton alterations associated with protein (spectrin) degradation, and loss of plasma 
membrane phospholipid asymmetry leading to the externalization of phosphatidylserine in 
the erythrocyte membrane (111, 112). The exposure of phosphatidylserine and further eat-
me-signals at the cell surface triggers, and the decrease of cell volume facilitate, the 
engulfment of the dying cells by phagocytes (113). Hence, the term “eryptosis” was coined 
recently (114) to describe erythrocyte cell death characterised by cell shrinkage, membrane 
blebbing, activation of proteases, and phosphatidylserine exposure at the outer membrane 
leaflet which are typical features of apoptosis in nucleated cells (115-117). 
1. 3. 1. Normal erythrocyte membrane and cation transport  
The non-nucleated erythrocyte is unique among human cells in that its plasma membrane 
accounts for all of its diverse antigenic, transport, and mechanical characteristics. The 
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discoid shape of the red cell evolves from the multilobulated reticulocyte during 48 hours 
of maturation first in the bone marrow and then in the circulation (118). 
The structural organization of the human red cell membrane enables it to undergo large 
reversible deformations while maintaining its structural integrity during its 4-month life 
span in the circulation. The red cell membrane exhibits unique material behaviour. It is 
highly elastic (100-fold softer than a latex membrane of comparable thickness), rapidly 
responds to applied fluid stresses (time constants in the range of 100 milliseconds), and is 
stronger than steel in terms of structural resistance. While a normal red cell can deform 
with linear extensions of up to approximately 250%, a 3% to 4% increase in surface area 
results in cell lysis. Hence an important feature of induced red cell deformations, both in 
vitro and in vivo, is that they involve no significant change in membrane surface area. 
These unusual membrane material properties are the result of an evolution-driven 
“engineering” process resulting in a composite structure in which a plasma membrane 
envelope composed of cholesterol and phospholipids is anchored to a 2-dimensional elastic 
network of skeletal proteins through tethering sites on cytoplasmic domains of trans-
membrane proteins embedded in the lipid bilayer (118). Direct interaction of several 
skeletal proteins with the anionic phospholipids affords additional attachments of the 
skeletal network to the lipid bilayer (113). 
The lipid bilayer is composed of equal proportions by weight of cholesterol and 
phospholipids (119). While cholesterol is thought to be distributed equally between the two 
leaflets, the four major phospholipids are asymmetrically disposed. Phosphatidylcholine 
and sphingomyelin are predominantly located in the outer monolayer, while most 
phosphatidylethanolamine and all phosphatidylserine (PS), together with the minor 
phosphoinositide constituents, are confined to the inner monolayer (120). Several different 
types of energy-dependent and energy-independent phospholipid transport proteins have 
been implicated in generating and maintaining phospholipid asymmetry. “Flippases” move 
phospholipids from the outer to the inner monolayer while “floppases” do the opposite 
against a concentration gradient in an energy-dependent manner. In contrast, “scramblases” 
move phospholipids bi-directionally down their concentration gradients in an energy-
independent manner (121, 122). 
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The maintenance of asymmetric distribution of phospholipids, in particular exclusive 
localization of PS and phosphoinositides to the inner monolayer, has several functional 
implications. Because macrophages recognize and phagocytose red cells that expose PS at 
their outer surface, the confinement of this lipid in the inner monolayer is essential if the 
cell is to survive its frequent encounter with macrophages of the reticuloendothelial 
system, especially the spleen. Loss of lipid asymmetry leading to exposure of PS on the 
outer monolayer has been suggested to play a role in premature destruction of thalassemic 
and sickle red cells. Furthermore, the restriction of PS to the inner monolayer also inhibits 
the adhesion of normal red cells to vascular endothelial cells, thereby ensuring unimpeded 
transit through the microvasculature (123, 124). 
More than fifty trans-membrane proteins with variable abundance, ranging from a few 
hundred to a million copies per red cell, have been characterized. A large fraction of these 
trans-membrane proteins define the various blood group antigens. The membrane proteins 
exhibit diverse functional heterogeneity, serving as transport proteins. Most proteins 
associated with the erythrocyte membrane are involved in active and passive ion transport, 
i.e. processes to maintain erythrocyte homeostasis. Other erythrocyte membrane proteins 
may act as adhesion proteins involved in interactions of red cells with other blood cells and 
endothelial cells, and also as signalling receptors (123, 125). 
Membrane proteins with transport function include band 3 (anion transporter), aquaporin 1 
(water transporter), GLUT-1 (glucose and L-dehydroascorbic acid transporter), Kidd 
antigen protein (urea transporter), RhAG (gas transporter, probably of carbon dioxide), 
Na+-K+-ATPase, Ca++ ATPase, Na+-K+-2Cl− cotransporter, Na+-Cl− cotransporter, Na+-K+ 
cotransporter, K+-Cl− cotransporter, and Gardos Channel (123, 126). 
1. 3. 1. 1. Na+ / K+ pump in non-infected erythrocytes 
The Na+/K+ pump mechanism of human erythrocytes is well understood. It builds up and 
maintains a high intracellular K+ ([K+]i) and a low intracellular Na+ ([Na+]i) concentration. 
The ouabain-sensitive Na+/K+-ATPase in the erythrocyte membrane pumps 2 K+ ions into 
versus 3 Na+ out of the cell, thereby generating opposing chemical gradients for the two 
ions. The pumping helps to build up the membrane potential and counterbalances the 
"leak" of the Na+ and K+ ions down their respective concentration gradients via various 
cotransporters, exchangers, and channels that adjust a steady-state cytoplasmic [Na+]-to-
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[K+] ratio of 0.12-0.16 in normal human erythrocytes (127). Intraerythrocytic Na+ and K+ 
concentrations have been determined as approximately 10 to 20 mM and 140 mM, 
respectively. Several cation channels that may contribute to the cation leak have been 
identified electrophysiologically (128). 
1. 3. 1. 2. Nonselective cation channels in non-infected erythrocytes 
Whole-state and nystatin-perforated patch-clamp single-channel recordings have led to the 
discovery of nonselective cation (NSC) channels in the human RBC membrane that are 
activated by strong depolarization of the membrane potential (129, 130). These voltage-
gated NSC channels are stimulated through nicotinic acetylcholine and PGE2 receptors. 
They are permeable to divalent cations such as Ca2+, Ba2+, and Mg2+ (131, 132), and 
exhibit a hysteresis-like voltage-dependent gating (133). In addition, voltage-independent 
NSC channels have been discovered. Experiments with simultaneous activity of both 
channel types suggest their differential regulation (114). 
Activation of the voltage-independent NSC channels occurs within minutes upon 
replacement of extracellular Cl- by gluconate (115, 116), similar when extracellular Cl- is 
replaced by NO3-, Br-, or SCN-. Furthermore, voltage-independent NSC channels are 
activated when the ionic strength of the bath solution is lowered by isosmotic substitution 
of NaCl with sorbitol, indicating that the underlying process is probably identical with that 
of the Na+ and K+ permeability increase upon incubation of human erythrocytes in low 
ionic strength medium (129, 132). Decrease of the extracellular Cl- concentration activates 
these cation channels. Remarkably, the anion channel/transporter inhibitor 
diisothiocyanatostilbene-2′,2-disulfonic acid (DIDS) directly inhibits K+ efflux in low ionic 
strength medium paralleled by inhibition of Cl- exchange. Moreover, whole-cell recordings 
show that upon extracellular Cl- removal DIDS prevents activation of the NSC channel, 
while having no effect on the activated cation channels (134). Furthermore, cation channel 
activity strongly depends on the cytosolic (i.e., pipette) Cl- concentration (135), suggesting 
that a DIDS-sensitive pathway equilibrates the Cl- concentrations between the cytoplasmic 
and extracellular membrane face and that intracellular rather than extracellular Cl- ions 
modulate the cation channel activity (135). The voltage-independent channels hardly 
discriminate between monovalent cation channels (cation permselectivity in the rank order 
of Cs+ > K+ > Na+ = Li+ >> NMDG+) and have a Ca2+-permeability similar to that of 
voltage-gated NSC channels (128). 
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1. 3. 1. 3. Ca2+ activated K+ channels (Gardos channels) 
The erythrocyte uses at least four well-characterized K+ transport mechanisms: the K+Cl- 
cotransporter, a NaK2Cl cotransporter, a Na+/K+ ATPase (a sodium pump) and a Ca2+ 
activated K+ channel (Gardos channels) (136). The gene for the Gardos channel in 
erythrocytes is the 4th member of the potassium intermediate/small conductance calcium-
activated channel subfamily N (KCNN4; aliases: hsK4 (human small conductance 
potassium channel 4), hIK1 (human intermediate conductance potassium channel) (115, 
137). Gardos channels have been characterized by single channel recordings (138). They 
play an important role in the regulation of cell volume  and are major factors in HbS/S 
RBC dehydration (125). 
Gardos channel activity is dependent on the free Ca2+ concentration at the cytoplasmic 
membrane face. , Concomitant with an increase in free [Ca2+]i from 500 nM to 60 µM its 
open probability increases from 0.1 to 0.9. Ca2+ acts via binding to calmodulin 
constitutively associated with the Gardos channels (139). In addition to Ca2+, channel 
activity is dependent on intracellular K+, and inhibited by extracellular Na+, K+. In 
addition, protein kinase A (PKA) reportedly induces a dramatic enhancement of Gardos 
channel activity, possibly by modulating the Ca2+ sensitivity (138). 
In non-stressed and non-stimulated human erythrocytes the fractional Gardos K+ channel 
activity is low, resulting in a very low membrane potential (≤ -10 mV) (140). As a 
consequence, human erythrocytes relatively have high intracellular Cl- concentrations. 
Activation of Gardos channels by increased intraerythrocytic Ca2+ levels (≥ 150 nM) leads 
to hyperpolarization of the RBC membrane potential close to the K+ equilibrium potential 
(115, 141). This imposes an outwardly directed electrochemical Cl- gradient across the 
RBC membrane, driving Cl- and K+ into the extracellular space, followed by osmotically 
obliged water efflux. The Gardos channel inhibitors clotrimazole and charybdotoxin (138, 
142), or Cl- channel blocker 5-Nitro-2- (3-phenylpropylamino) benzoic acid (NPPB) blunt 
phosphatidylserine (PS) exposure, hyperosmotic and Ca2+-stimulated isosmotic cell 
shrinkage, confirming the contribution of Gardos and anion channels to KCl and water 
efflux during RBC shrinkage (143, 144). 
Increase in free [Ca2+]i therefore favors RBC shrinkage (Gardos effect) (144) subsequently 
decreased RBC deformability under isosmostic conditions, measured as decreased cell size 
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or filterability (141). The Gardos effect is dependent on the extracellular Ca2+ 
concentration and is sensitive to amiloride (115). During complement activation rising 
cytosolic calcium triggers the Gardos effect, thus limiting the colloidosmotic swelling and 
lysis of erythrocytes (145). 
1. 3. 2. Mechanisms of erythrocyte cell death or eryptosis  
Eryptosis is triggered by erythrocyte injury after several stressors, including oxidative 
stress. Besides caspase activation after oxidative stress, two signalling pathways converge 
to trigger eryptosis: (a) formation of prostaglandin E2 leads to activation of Ca2+ 
permeable cation channels, and (b) the phospholipase-A2 mediated release of platelet-
activating factor activates a sphingomyelinase, leading to formation of ceramide. Increased 
cytosolic Ca2+ activity and enhanced ceramide levels lead to membrane scrambling with 
subsequent phosphatidylserine exposure. Moreover, Ca2+ activates Ca2+-sensitive K+ 
channels, leading to cellular KCl loss and cell shrinkage. In addition, Ca2+ stimulates the 
protease calpain, resulting in degradation of the cytoskeleton (108, 146). 
1. 3. 2. 1. Role of prostaglandins in stimulation of erythrocyte cation channels  
Intriguing evidence points to a role of prostaglandins in the regulation of eryptosis. 
Hyperosmotic shock and Cl--removal trigger the release of prostaglandin E2 (PGE2). 
PGE2 in turn activates the cation channels, increases the cytosolic Ca2+ concentration, and 
stimulates phosphatidylserine exposure at the erythrocyte surface. The activation of the 
cation channels by Cl- -removal is abolished by the cyclooxygenase inhibitor diclofenac. 
Moreover, phospholipase-A2 inhibitors quinacrine and palmitoyl trifluoromethyl ketone 
and cyclooxygenase inhibitors acetylsalicylic acid and diclofenac blunt the increase of 
phosphatidylserine exposure following Cl- removal. PGE2 further activates the Ca2+ 
dependent cysteine endopeptidase calpain, an effect, however, apparently not required for 
stimulation of phosphatidylserine exposure but playing a role in the degradation of the 
cytoskeleton (141). 
1. 3. 2. 2. Role of Ca2+ sensitive K+ channels (Gardos channels) in eryptosis  
Calcium ions entering erythrocytes do not only activate the scramblase but in addition 
stimulates the Ca2+ sensitive “Gardos” K+ channels in erythrocytes (147). The activation of 
the channels leads to hyperpolarization of the cell membrane driving Cl- in parallel to K+ 
into the extracellular space. The cellular loss of KCl favours cell shrinkage. Moreover, the 
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cellular loss of K+ presumably participates in the triggering of “eryptosis”. Increase of 
extracellular K+ or pharmacological inhibition of the Gardos channels by clotrimazole or 
charybdotoxin do not only blunt the cell shrinkage but also decrease the phosphatidylserine 
exposure following exposure to ionomycin. Presumably, cellular loss of K+ somehow 
stimulates “eryptosis” as has been shown for apoptosis of nucleated cells (148). As PGE2 
increases cytosolic Ca2+ activity, it similarly activates the Ca2+ sensitive “Gardos” K+ 
channels with subsequent cell shrinkage (149). 
1. 3. 2. 3. Role of protein kinase C in eryptosis 
Erythrocyte energy depletion enhances phosphorylation of membrane proteins by protein 
kinase C (PKC), leads to subsequent phosphatidylserine exposure at the cell surface and 
triggers cell shrinkage, effects mimicked by stimulation of protein kinase C (PKC) with 
phorbol esters or inhibition of protein phosphatises with okadaic acid (150). PKC 
activation has previously been shown to stimulate erythrocyte Ca2+ entry and 
phosphatidylserine exposure (151). PKC is a family of serine/threonine-specific protein 
kinases consisting of 10 members and requiring Ca2+, diacylglycerol, and a phospholipid 
for activation. PKC isoenzymes play an essential role in the regulation of diverse cellular 
functions including proliferation, differentiation, and apoptosis. Human erythrocytes 
express PKC isoenzymes mediating the phosphorylation of cytoskeletal proteins, such as 
band 4.1, 4.9, and adducing the human Na+/H+ exchanger (NHE 1) (151, 152). 
1. 3. 2. 4. Role of oxidative stress and caspase activation in eryptosis 
Oxidative stress resulting from exposure to tert-butylhydroperoxide or peroxynitrite, for 
instance, is a major cause of erythrocyte injury (153, 154). It has been shown to activate 
aspartyl and cysteinyl proteases (155). Caspases have been shown to be expressed in 
erythrocytes, to cleave the anion exchanger band 3 in vitro (155), and to stimulate 
phosphatidylserine exposure of erythrocytes (156). Conversely, eryptosis after ionomycin 
or hyperosmotic shock does not require activation of caspases (157). Besides its effect on 
caspases, oxidative stress or defects of antioxidative defence, enhance Ca2+ entry via 
activation of the cation channels and thus stimulate eryptosis at least partially through 
channel activation (158). Oxidation of erythrocytes leads to an increase of the cation 
permeability of the membrane, Oxidation with tert-butylhydroperoxide also enhanced 
erythrocyte annexin-V binding as a measure of phosphatidylserine exposure by some six 
folds. Interestingly, not all erythrocytes of one population showed the same sensitivity 
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against oxidative stress, and only one third of the population was shown to be annexin-V 
positive (141). Oxidative stress further activates erythrocyte Cl- channels (159), which are 
required for erythrocyte shrinkage and thus also participate in the triggering of eryptosis 
(143). Antioxidants, such as vitamin E (160, 161), glutathione (162), or the semi-synthetic 
flavonoid 7-monohydroxyethylrutoside may protect erythrocytes from oxidative stress and 
thus presumably from eryptosis (163). 
1. 3. 2. 5. Role of platelet-activating factor (PAF) and stimulation of sphingomyelinase 
in eryptosis 
Erythrocyte shrinkage triggers the formation of platelet-activating factor (PAF) which is 
involved in the regulation of inflammation, thrombosis, atherogenesis, and cardiovascular 
function (164). PAF then stimulates a sphingomyelinase, leading to the breakdown of 
sphingomyelin and release of ceramide from erythrocytes (122). Osmotic shock thus leads 
to the appearance of ceramide at the erythrocyte surface. At least partially because of 
ceramide formation, PAF triggers scrambling of the cell membrane with 
phosphatidylserine exposure at the erythrocyte surface. C6- ceramide as well as treatment 
with purified, bacterial sphingomyelinase similarly triggers phosphatidylserine scrambling 
(165). Moreover, eryptosis after osmotic shock is blunted by the sphingomyelinase 
inhibitor 3,4-dichloroisocoumarin. PAF further activates Ca2+-sensitive K+ channels 
(Gardos channels) in the erythrocyte cell membrane (166). Conversely, PAF is released 
from erythrocyte progenitor cells on increase of cytosolic Ca2+ activity (114). The 
signalling through PAF does, however, not necessarily require elevated cytosolic Ca2+ 
concentrations, and enhanced PAF levels at least partially account for Ca2+-independent 
eryptosis (164). 
1. 3. 3. Eryptosis inhibitors 
Erythropoietin is a potent inhibitor of erythrocytic progenitor cells apoptosis, and also 
inhibits the suicidal death of mature erythrocytes. The hormone is effective through 
inhibition of the Ca2+-permeable cation channels. The anti-eryptotic effect of 
erythropoietin presumably accounts for its ability to increase the life span of circulating 
cells. Dopamine, isoproterenol, and epinephrine similarly inhibit the Ca2+-permeable cation 
channels and thus interfere with eryptosis. The effect is presumably not relevant for 
physiologic regulation, as the concentrations of catecholamines required exceed those 
encountered in vivo. However, animal experiments revealed that the hematotoxicity 
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(including red blood cell counts) of cyclophosphamide has been reduced by simultaneous 
dopamine treatment. Thus, administration of dopamine at pharmacologic doses may well 
be therapeutically applicable for the suppression of eryptosis (167). 
1. 3. 4. Clinical conditions associated with eryptosis 
A variety of clinical conditions decrease the life span of mature erythrocytes by facilitating 
eryptosis. Increased sensitivity of sickle cells and of glucose 6-phosphate dehydrogenase– 
deficient cells to osmotic shock, oxidative stress and glucose depletion has been observed 
previously. The enhanced susceptibility to eryptosis is believed to decrease the erythrocyte 
life span in those disorders (168). 
Similarly, iron-deficient erythrocytes are more sensitive to eryptosis. The enhanced 
eryptosis is at least partially the result of enhanced cation channel activity. Presumably, the 
decreased volume of iron-deficient erythrocytes decreases the threshold for the activation 
of the channel. Interestingly, the enhanced exposure of phosphatidylserine on the surface 
of iron-deficient erythrocytes coincides with a substantial decrease of the life span of iron-
deficient erythrocytes (169). Eryptosis is further triggered by exposure of erythrocytes to 
lead or mercury, or by treatment with plasma from patients with recurrent hemolytic-
uremic syndrome. Thus, the typical anemia after lead intoxication is at least partially due to 
enhanced eryptosis. Oxidant injury of erythrocytes and/or erythrocyte precursors may 
further occur in HIV (162). 
Even though it is a pathophysiologic mechanism, eryptosis serves an important physiologic 
function (i.e., the prevention of hemolysis). Energy depletion, defective Na+/K+ATPase, or 
enhanced leakiness of the cell membrane eventually leads to cellular gain of Na+ and Cl– 
with osmotically obliged water, resulting in subsequent cell swelling (170). Initially, the 
entry of Na+ is compensated by cellular loss of K+; the decrease of the K+ equilibrium 
potential leads, however, to gradual depolarization, which favours the entry of Cl-. The cell 
swelling jeopardizes the integrity of the cell membrane. Rupture of the cell leads to release 
of hemoglobin, which may be filtered at the glomeruli of the kidney, precipitate in the acid 
lumen of the tubules, obliterate the tubules, and thus lead to renal failure. The 
phosphatidylserine exposure at the cell surface allows the macrophages to recognize 
defective erythrocytes and to clear them from circulating blood before hemolysis. 
Moreover, the activation of the Gardos K+ channel delays swelling and disruption of 
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defective erythrocytes, thus expanding the time allowed for macrophages to clear the 
injured erythrocytes from circulating blood (167). 
1. 3. 5. Eryptosis in malaria 
1. 3. 5. 1. Stimulation of membrane transport in P. falciparum infected erythrocytes 
and activation of ion channels 
A prerequisite for intracellular survival of pathogens is an adequate supply of nutrients and 
disposal of waste products (171). Additional transport systems for nutrient supply and 
disposal of waste products are needed particularly during infection of erythrocytes with 
Plasmodium species. Before infection, the substrate turnover of erythrocytes is low. Since 
they do not synthesize proteins, DNA or membrane components, they have no need for 
amino acids, nucleic acids, lipids or most of the vitamins. The replicating Plasmodium, 
however, has extensive requirements for all of these nutrients and, to fuel the replication 
process, Plasmodium parasites consume large amounts of glucose. An infected erythrocyte 
takes up 40–100 times more glucose than a non-infected cell and releases the 
corresponding amounts of lactic acid (172). To gain access to the necessary nutrients and 
to dispose the waste products, Plasmodium induces the so-called new permeability 
pathway (NPP). This pathway mediates the transport of electrolytes, sugars, nucleic acids, 
membrane components and other substances across the erythrocyte membrane. In addition 
to nutrient uptake and lactate disposal the NPP contributes to the strategy of the pathogen 
to counteract swelling of the host cell by decreasing the colloid-osmotic pressure in the 
host cytosol. The parasite digests haemoglobin in excess (i.e. more than needed for its 
protein biosynthesis) and exports the haemoglobin-derived amino acids via the NPP thus 
preventing host cell swelling and lysis (173). NPP further allows the entry of Na+ and Ca2+ 
into the host cell, thus adjusting the electrolyte composition of the host cytosol to the needs 
of the parasite. Starting >15 h post-infection, K+ in the host cytosol is replaced increasingly 
by Na+. The parasite most probably requires an outwardly directed K+ and an inwardly 
directed Na+ gradient across its plasma membrane since decreasing these gradients 
experimentally in vitro abolishes parasite growth. In addition, absence of extracellular Ca2+ 
disrupts the intraerythrocyte survival of the pathogen (174). The necessity of the NPP for 
Plasmodium’s survival is illustrated by the fact that several inhibitors of this pathway 
eventually kill the pathogen within the erythrocyte (175). On the other hand, the 
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Plasmodium species imposes oxidative stress on host cells, and this has been proposed to 
be required for the activation of the cation channels (135). 
1. 3. 5. 2. Induction of eryptosis by P. falciparum infection 
The opening of cation channels in the host cell by P. falciparum is expected to increase the 
cytosolic Ca2+ activity and thus to induce eryptosis. However, most of the Ca2+ entering the 
parasitized erythrocyte is either extruded across the host cell membrane or taken up by the 
pathogen so that cytosolic free Ca2+ activity remains low (176). Nevertheless, some in vitro 
studies have shown infection with P. falciparum increase the number of erythrocytes that 
expose phosphatidylserine at the outer membrane leaflet, (177) while another study could 
not detect breakdown of the phospholipid asymmetry. Infection with P. falciparum 
increases the formation of ceramide (122) that in turn increases the Ca2+ sensitivity of the 
erythrocyte scramblase and may account for the stimulation of the scramblase even at low 
or only slightly enhanced cytosolic Ca2+ concentrations. Beyond that, Ca2+ independent 
mechanisms may participate in the triggering of eryptosis. As observed in nucleated cells 
the cellular loss of K+ via the induced cation channel is expected to augment the activation 
of the erythrocyte scramblase and thus adds to the stimulation of the phosphatidylserine 
exposure (178). 
1. 3. 5. 3. Role of eryptosis in parasitized erythrocytes 
Human erythrocytes infected with trophozoite and shizont stages of P. falciparum may 
adhere to endothelial cells lining the post-capillary venules. Adhesion of the infected 
erythrocyte to the endothelium involves receptors in the endothelial membrane such as 
CD36, secreted proteins such as thrombospondin, parasite-encoded molecules such as P. 
falciparum erythrocyte membrane 1 (PfEMP1) and a modified erythrocyte anion 
exchanger (AE1, band 3) (177). In particular, exposure of phosphatidylserine at the outer 
membrane leaflet contributes to erythrocyte-endothelium adhesion via binding to 
thrombospondin and CD36 receptor. Thus “eryptosis” of parasitized erythrocytes may 
contribute to tissue sequestration, which is thought to avoid splenic clearance of the 
parasitized erythrocyte and to favour parasite development in a low oxygen pressure 
microenvironment. On the other hand “eryptosis” may result in clearance of parasitized 
erythrocytes. As macrophages are equipped with receptors specific for phosphatidylserine, 
erythrocytes exposing phosphatidylserine at their surface will be recognized, bound, 
engulfed and degraded rapidly. Thus, infected erythrocytes are liable to be eliminated as 
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soon as they expose phosphatidylserine. The removal of the infected erythrocyte would of 
course clear the pathogen as well, since it would be similarly degraded by lysosomal 
enzymes of the macrophages (179, 180). 
1. 4. Rodent malaria parasites as models for human malaria  
A wide range of investigations using rodent parasites have contributed to development and 
shaping of basic concepts in research of human diseases. Rodent malaria parasites are 
practical models for the experimental study of mammalian malaria. These parasites have 
proved to be analogous to human malaria in most essential aspects of structure, physiology 
and life cycle (181). Metabolic pathways are conserved between rodent and human malaria 
parasites. No gross differences in metabolic pathways have been reported in the various 
malaria parasites. The similarity in sensitivity of these parasites to anti-malarial drugs and 
other specific inhibitors emphasises the similarities in their metabolic processes. The life 
cycles and the different developmental stages of all rodent and human malaria parasites are 
largely comparable (182, 183). Rodent parasites are recognized as valuable model parasites 
for the investigation of the developmental biology of malaria parasites, parasite-host 
interactions, vaccine development and drug testing. The relationships of rodent parasites to 
other human malaria parasites in brief are: 
• The basic biology of rodent and human parasites is similar.  
• The genome organization and genetics is conserved between rodent and human parasites 
(184). 
• Housekeeping genes and biochemical processes are conserved between rodent and human 
parasites.  
• Methodologies for genetic modification are available for both types of parasites.  
• Rodent hosts with extensively characterised genetic backgrounds and transgenic lines are 
valuable and available tools for immunological studies.  
• The structure and function of vaccine candidate target antigens are conserved between 
rodent and human parasites. 
• The manipulation of the complete lifecycle of rodent parasites, including mosquito 
infections is simple and safe.  
• In vitro culture techniques for large-scale production and manipulation of different life 
cycle stages are available. For example, in vitro cultures of liver and mosquito stages 
provide tools to investigate the less accessible parts of the life cycle in the human  
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• The molecular basis of drug-sensitivity and resistance show similar characteristics in 
rodent and human parasites.  
• Rodent parasites allow in vivo investigations of parasite-host interactions and in vivo drug 
testing.  
The malaria parasites P. berghei which infects hamsters, rats and mice, is one of the many 
species of malaria parasites that infect mammals other than humans. A susceptible 
mosquito vector for P.berghei, which is widely used in the laboratory, is Anopheles 
stephensi (182, 184). 
1. 5. Pharmacological agents 
1. 5. 1. Gum Arabic 
Gum Arabic (GA) is a water-soluble dietary fibre derived from the dried gummy exudates 
of the stems and branches of Acacia Senegal (185). Chemically, GA is a polysaccharide of 
(1-3) linked β-D-galactopyranosyl units with branches of two to five units in length 
attached by (1-6) links to the main chain. Both the main chain and side chains contain α-L-
arabinofuranosyl, α-L-rhamnopyranosyl, β-D-glucuronopyranosyl, and 4-O-methyl-β-D-
glucuronopyranosyl units. Gum arabic is readily soluble in water without increasing 
viscosity (186). 
Gum Arabic is a highly heterogeneous material, but was separated into three major 
fractions by hydrophobic affinity chromatography (187). Most of the gum (88.4% of total), 
an arabinogalactan (AG), had a very low protein content (0.35%) and a molecular mass of 
3.8 - 105 Da. The second fraction (10.4% of total), an arabinogalactan-protein complex 
(AGP), contained 11.8% protein and had a molecular mass of 1.45 - 106 Da. The third 
fraction (1.2% of total gum), referred to as a low molecular weight glycoprotein (GP), had 
a protein content of 47.3%, and a molecular mass of 2.5 - 105 Da (GPC data). The major 
amino acids present in the protein of AG and AGP were hydroxyproline, serine and 
proline, whereas in GP, aspartic acid is the most abundant (188). 
Gum Arabic is primarily indigestible to both humans and animals. It is not degraded in the 
small intestine, but fermented in the large intestine by microorganisms to short-chain fatty 
acids, particularly butyric and propionic acids. Such degradation products are absorbed in 
the human colon and subsequently metabolized. In an experiment using an enrichment  
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culture of pig cecal bacteria, showed that a Prevotella ruminicola-like bacterium was the 
predominant organism that is most likely to be responsible for the fermentation of GA to 
butyrate and propionate (189, 190). 
Gum Arabic is widely used in both the pharmaceutical and food industries as an emulsifier 
and stabilizer of various products for human consumption. Examples include tablets or 
food applications such as puddings and fillings, frostings, candy, and chewing gum. The 
United States Food and Drug Administration recognize it as one of the safest dietary fibers 
(189, 191). 
Pharmacologically, GA has been claimed to act as an anti-oxidant, and to protect against 
experimental hepatic, renal and cardiac toxicities in rats. GA has been claimed to alleviate 
the adverse effects of chronic renal failure in humans. This could not be corroborated 
experimentally in rats (183). Reports on the effects of GA on lipid metabolism in humans 
and rats are contradicting, but mostly suggest that GA ingestion can reduce plasma 
cholesterol concentrations. GA has proabsorptive properties and can be used in diarrhoea. 
It enhances dental remineralization, and has some antimicrobial activity, suggesting a 
possible use in dentistry. GA has been shown to have an adverse effect on electrolyte 
balance and vitamin D in mice, and to cause hypersensitivity in humans (183). 
1. 5. 2. Amphotericin B 
Amphotericin B is a polyene antifungal agent with an in vitro activity against a wide 
variety of fungal pathogens. Amphotericin B exerts its antifungal effect by disruption of 
fungal cell wall synthesis because of its ability to bind to sterols, primarily ergosterol. This 
affinity may also account for its toxic effects against selected mammalian cells. 
Amphotericin B may be fungistatic or fungicidal, depending upon drug concentration and 
sensitivity of the pathogen (192). 
Oral preparations of amphotericin B are used to treat oral thrush; these are virtually 
nontoxic. The main i.v. use is in systemic fungal infections (eg. in immunocompromised 
patients), and in visceral Leishmaniasis. Aspergillosis, Cryptococcus infections (eg. 
meningitis) and Candidiasis are treated with amphotericin B. It is also used empirically in 
febrile immunocompromised patients who do not respond to broad-spectrum antibiotics 
(193). 
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1. 5. 2. 1. Mode of action 
As with other polyene antifungals, amphotericin B associates with ergosterol, a membrane 
chemical of fungi, forming a pore that leads to K+ leakage and fungal cell death. Recently, 
however, researchers found evidence that pore formation is not necessarily linked to cell 
death. The actual mechanism of action may be more complex and multi-faceted. 
Amphotericin B is believed to interact with membrane sterols (ergosterol) to produce an 
aggregate that forms a trans-membrane channel. Intermolecular hydrogen bonding 
interactions among hydroxyl, carboxyl and amino groups stabilize the channel in its open 
form, destroying activity and allowing the cytoplasmic contents to leak out (194). 
1. 5. 2. 2. Side effects 
Very often a most serious acute reaction after the infusion (1 to 3 hours later) is noted 
consisting of fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, 
dyspnea, and tachypnea. This reaction sometimes subsides with later applications of the 
drug and may in part be due to histamine liberation. An increase in prostaglandin-synthesis 
may also play a role. Often the most difficult decision has to be made, whether the fever is 
disease or drug-related. In order to decrease the likelihood and severity of the symptoms, 
initial doses should be low and increased slowly. The liposomal preparation obviously has 
a lower incidence of the syndrome. Acetaminophen, pethidine, diphenhydramine and/or 
hydrocortisone have all been used to treat or prevent the syndrome, but the prophylactic 
use of these drugs should be limited (195). 
Nephrotoxicity (kidney damage) is a major issue and can be severe and/or irreversible. It is 
much milder when amphotericin B is delivered in liposomes. Electrolyte imbalances (eg. 
hypokalemia and hypocalcemia) may also occur (196). 
1. 6. Rational of the study  
Targeting the pathogen with antimalarial drugs has only been partially successful because 
of the spread of drug-resistant parasites and the optimal use of effective drugs has always 
been a major concern. Hence all possibilities to combat this disease must be explored. The 
course of the disease is not only a function of the pathogen but is heavily influenced by 
properties of the host. Hence, studies must be carried out to fight infection by altering host 
physiology which decimates the problem of drug resistance and if successful, these  
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approaches may prove extremely useful, particularly in the treatment of resistant 
pathogens. Targeting at the accelerated clearance of the infected host cells is expected to 
provide protection against malaria.  
Pharmacological induction of phosphatidylserine exposure of ring stage-infected 
erythrocytes reportedly accelerates their clearance. Thus, manoeuvres accelerating 
eryptosis may result in premature clearance of the intraerythrocytic parasite and partially 
enhance the survival of Plasmodium berghei-infected mice. Importantly, counteracting 
Plasmodia by inducing eryptosis is not expected to generate resistance of the pathogen, as 
the proteins involved in suicidal death of the host cell are not encoded by the pathogen and 
thus cannot be modified by mutations of its genes.  
In this study we are interested in investigating the role of phosphatidylserine (PS) exposure 
and eryptosis which may allow the pharmacological manipulation of erythrocyte survival 
and hence of the malaria disease course. This may be achieved by determining the effect of 
eryptosis inducing drugs on the proliferation and survival of the Plasmodium pathogen. 
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1. 7. The objectives of the study 
1. 7. 1. General objective 
The aim of the present study is to investigate the effect of amphotericin B or gum Arabic 
administration on eryptosis of infected cells and their influence on the course of malaria in 
P. berghei infected mice. 
1. 7. 2. Specific objectives 
1. To determine the effect of amphotericin B or butyrate on in vitro growth and DNA 
amplification of P. falciparm infected erythrocytes. 
2. To determine the effect of amphotericin B or butyrate on the cytosolic Ca2+ activity 
of P. falciparm infected and non-infected erythrocytes. 
3. To determine the effect of amphotericin B or butyrate on the phosphatidylserine 
exposure on P. falciparm infected and non-infected erythrocytes. 
4. To determine the effect of amphotericin B or gum Arabic administration on 
eryptosis of infected cells and their influence on the course of malaria in P. berghei 
infected mice. 
5. To determine the significance of phosphatidylserine exposure in clearance and 
elimination of infected erythrocytes.  
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2. Materials and methods 
2. 1. Animals 
Experiments were carried out on 4 to 5-month-old wild-type SV129/mJ mice of either sex 
(n = 6 male, 8 female for each one of the three series) in gum Arabic and amphotericin B 
experiments. The animals were housed under controlled environmental conditions (22-
24°C, 50-70% humidity, and a 12-h light/dark cycle). Throughout the study, mice had free 
access to standard pelleted food (C1310, Altromin, Heidenau, Germany) and tap water or 
GA solution, as indicated. All animal experiments were conducted according to the 
guidelines of the American Physiological Society and the German law for the care and 
welfare of animals, and were approved by local authorities in Eberhard Karls University of 
Tübingen, Germany. (Registration number PY 2/06). Mouse erythrocytes were drawn from 
animals by retroorbital venopuncture or by incision of the tail vein. 
2. 2. Parasites 
Plasmodium falciparum BINH (197) and Plasmodium berghei ANKA (198) were a kind 
gift from the Institute of Tropical Medicine in Tuebingen, Germany. All chemicals and 
equipments used in this study are shown in appendix 1. 
2. 3. Infection of mice 
For infection of mice Plasmodium berghei ANKA-parasitized murine erythrocytes (1x106) 
were injected intraperitoneally into wild-type mice (199, 200). 
2. 4. Gum Arabic treatment 
Gum Arabic in powder form was provided as a generous gift from Dar Savanna, Ltd., 
Khartoum, Sudan (www.ssgums.com). It is a 100% natural extract powder produced 
mechanically from the wildly grown Acacia senegal tree, with a particle size of <210 µm. 
Its quality conforms to the food and pharmaceutical requirements of the Food and 
Agriculture Organization of the United Nations (FAO), the British Pharmacopoiea (BP), 
the United States Pharmacopoiea (USP), and the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA). 
Experiments were carried out on wild-type SV129/mJ mice of either sex (n = 6 male, 8 
female for each one of the three series). Starting from the day of infection, animals were 
provided with 10% (w/w) GA dissolved in tap water (100 g/L). Preparations were 
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refreshed every day during the treatment. The effects of GA treatment were investigated 
starting from day 8 after the infection. The intake corresponded to a dose of approximately 
10 g/kg body weight/day. Blood was collected from the mice 8 days after infection by 
incision of the tail. Parasitemia was determined by Syto-16 staining in FACS analysis or 
using Giemsa stain. 
2. 5. Amphotericin B administration 
Experiments were carried out on six male mice for control and other six mice for 
Plasmodium berghei infected group in each one of the three series of the experiment. 
Amphotericin B (1.4 mg/kg body weight for three successive days) was administered 
subcutaneously from the eighth day of infection. Blood was collected from the mice 8 days 
after infection by the incision of the tail. Parasitemia was determined by Syto-16 staining 
in FACS analysis and Giemsa stain. 
2. 6. Preparation of human erythrocytes 
Human erythrocytes were drawn from healthy volunteers. They were used after separation 
by centrifugation for 25 min; 2000 g over Ficoll (Biochrom KG, Berlin, Germany). The 
buffy coat and upper 10-20% of the red blood cells were discarded; the remaining pellet 
was used for experiments after washing three times in phosphate buffer saline. The RBCs 
were stored at 4°C until use (2-5 days). Experiments were performed at 37°C in Ringer 
solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO
4
, 32 N-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid (HEPES)/NaOH (pH 7.4), 5 glucose, 1 CaCl
2 
or RPMI 1640 
medium. Blood donors gave their informed consent and the study was approved by the 
Ethical Committee of Eberhard Karls University of Tübingen, Germany (project number: 
184/2006V). (Appendix-2 protocol 1) 
2.7. Investigations 
2.7.1. In vitro culture of Plasmodium falciparum infected human erythrocytes 
For infection of human erythrocytes, the P. falciparum strain BinH (197) was grown in 
vitro (135) in human erythrocytes. Cultures were maintained continuously by routine 
passage in fresh and stored human erythrocytes. Parasites were cultured as described 
earlier (201, 202) at a hematocrit of 2-5% and a parasitemia of 2-10% in RPMI 1640 
medium supplemented with 0.5% Albumax II (Gibco, Karlsruhe, Germany), 0.13 µM 
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hypoxanthine, 2 mM L-glutamine (Gibco, Karlsruhe, Germany), 25 mM HEPES/NaOH 
pH 7.4 (Sigma-Aldrich, Schnelldorf, Germany), 20 µg/ml gentamycin (Gibco, Karlsruhe, 
Germany) in an atmosphere of 90 % N
2
, 5 % CO
2
, 5 % O
2
.  
The dilution factors (Df) for splitting the infected RBCs suspension in order to maintain 
the P. falciparum in vitro culture were calculated as follows: 
Df = mP * V(RBC) / dP * dV(RBC)  
Fresh blood was added according to the following formula: 
dV(RBC) – (V(RBC) )/ Df  
Where mP: measured parasitemia; V(RBC): volume of packed erythrocytes in the culture 
flask; dP: desired parasitemia; dV(RBC): desired volume of packed erythrocytes in the 
flask. The volume of the medium was adjusted according to the degree of parasitemia and 
the time until the next medium change (203) (Appendix-2 protocol 2). 
2.7. 1. 1. Freezing and sawing of parasites 
From time to time samples with high, i.e. ≥ 20 % parasitemia, predominantly containing 
ring stages were deep frozen in liquid nitrogen for stock purposes. The cell pellet obtained 
after centrifugation (450g / 8 min at RT) was mixed with an equal volume of freezing 
solution, sterile transferred to a 2.0 ml cryotube vial and directly deep frozen in liquid 
nitrogen. For defreezing the parasites from cryotubes containing infected RBCs (> 20 % 
parasitemia) were thawed quickly at 37°C in a water bath (3-5 min). The contents were 
transferred to a 15 ml falcon tube and centrifuged (450g / 4 min at room temperature). The 
supernatant was discarded. A volume of sterile filtered 3.5 % NaCl solution equal to cell 
pellet volume (V(RBC)) was added at a rate of 1 - 2 drops per second while gently shaking 
the tube. Finally the liquid was mixed with a pipette. After centrifugation at 450g for 4 min 
the supernatant was discarded. The RBC pellet was carefully suspended in original RPMI 
1640 medium (2*V (RBC)). Washing was repeated twice. The remaining cell pellet was 
re-suspended in complete medium and transferred to a culture flask. Fresh RBCs were 
added (amount depending on V(RBC)). The culture flask was filled with 90% N
2 
/5% O
2 
/ 
5% CO
2 
(Appendix-2 protocol 3). 
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2. 7. 1. 2. Isosmotic sorbitol synchronization of P. falciparum infected human 
erythrocytes 
The P. falciparum BinH strain was cultured and synchronized to the ring stage by sorbitol 
treatment (197). Briefly, the infected RBCs (>5% parasitemia) were spinned down at 
600×g and re-suspended in isoosmotic sorbitol solution (in mM: 290 sorbitol, 5 glucose, 5 
HEPES/NaOH, pH 7.4) for 20 min at 21°C in continuous shaking. Then the cells were 
washed twice in malaria culture medium and sub-culutred for further experiments 
(Appendix-2 protocol 4). 
2. 7. 1. 3. In vitro P. falciparum growth assay 
For the in vitro growth assay, synchronized parasitized erythrocytes were aliquoted in 96-
well plates (200 µl aliquots,0.5- 1% hematocrit, 0.5 –2 % parasitemia) and grown for 48 h 
in serum-free Albumax II (0.5%)-supplemented RPMI medium (159) (Appendix-2 
protocol 5). The erythrocytes were grown in the presence or absence of different 
concentrations of sodium butyrate or amphotericin B. The parasitemia of human 
erythrocytes were assessed at time 0 and after 48 h of culture by flow cytometry (FACS 
Calibur, Becton Dickinson, Heidelberg, Germany). Parasitemia was defined by the 
percentage of erythrocytes stained with the DNA/RNA specific fluorescence dye Syto16 
(20 nM final concentration, Molecular Probes, Göttingen, Germany). Briefly, RBCs were 
incubated with Syto16, diluted in PBS or annexin binding buffer at 37°C. The staining 
procedure was performed for around 30 – 40 min for infected human RBCs. Syto16 green 
fluorescent nucleic acid stain bound to DNA has a maximum excitation/absorption 
wavelength of 488 nm, which corresponds to the argon line of the single-laser of the FACS 
Calibur used, and a maximum emission wavelength of 518 nm. Bound to RNA the 
absorption maximum is at 494 nm, the emission maximum at 525 nm. This green emission 
is detected in the Fluorescence 1 (FL-1) channel with a detector for an emission 
wavelength of 530 ± 15nm. FACS analysis proved a more sensitive technique for 
determining parasitemia than either Giemsa or Field´s rapid staining. (Appendix-2 protocol 
6). In mice the course of parasitemia (=percentage of infected cells) was determined in 
Giemsa stained blood films made from tail blood. The thick blood film was air-dried and 
fixed with methanol. 2% Giemsa solution (Sigma) was added for 30 min. The slide was 
rinsed with water and again dried. Then, the slides were analysed under a Leica CM E light 
microscope (100 X, oil immersion) (204) (Appendix-2 protocol 7). 
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2. 7. 2. Intraerythrocytic DNA amplification of P. falciparum 
To estimate the DNA/RNA amplification in a further series of experiments, the culture was 
ring stage-synchronized and re-synchronized after 6 h of culture (to narrow the 
developmental parasite stage), aliquoted (200 µl aliquots, 2 % hematocrit and 10 % 
parasitemia) and cultured for further 16 h. The erythrocytes were cultured in the presence 
or absence of different concentrations of sodium butyrate or amphotericin B. Thereafter, 
the DNA/RNA amount of the parasitized erythrocytes was determined by Syto16 
fluorescence as a measure of intraerythrocytic parasite copies. 
2. 7. 3. Annexin binding experiments (Determination of phosphatidylserine exposure) 
Suspensions with non-infected RBCs were stained with annexin V-FLUOS. Suspensions 
with P. falciparum infected RBCs were stained with annexin V-568 and/or with the DNA 
dye Syto16 to assess PS exposure in the outer leaflet of the RBC membrane and the 
percentage of infected RBCs, respectively (205). (Appendix-2 protocol 8) 
For annexin binding, RBCs were washed, re-suspended in annexin-binding buffer, stained 
with annexin V-568 (dilution 1:50) or annexin V-FLUOS (dilution 1:100), and incubated 
for 20 min at RT in Ca2+-free annexin binding buffer. AnnexinV binding to negatively 
charged phospholipids (with a high specificity for PS) is Ca2+-dependent. Therefore an 
annexin binding buffer containing Ca2+ was used. Syto16 (final concentration of 30 nM) 
was co-incubated in the annexin binding buffer for 20 min at RT for double-staining 
purposes. Samples were diluted 1:5 with annexin binding buffer just before FACS analysis. 
Cells were analyzed by flow cytometry. Fluorescence 1, FL-1 (detector for an emission 
wavelength of 530 ± 15 nm) was either an indicator of annexin V-FLUOS fluorescence 
intensity (excitation: 450 - 500 nm, emission: 515 -565 nm) (simple staining for annexin); 
or of Syto16 fluorescence (maximum excitation wavelength: 488 nm for DNA, 494 nm for 
RNA, maximum emission wavelength: 518 nm for DNA, 525 nm for RNA).  Syto16 
fluorescence was taken to reflect the degree of parasitemia. Fluorescence 2, FL-2 (detector 
for an emission wavelength of 585 ± 21 nm) or FL-1 was used to determine the annexin 
fluorescence of Annexin V-568 or Annexin Fluos, respectively, i.e. the percentage of PS 
exposing cells. Annexin V-568 has an absorption spectrum from 450 – 650 nm, a 
maximum at 578 nm, an emission spectrum from 560 nm up to > 700 nm with a maximum 
at 603 nm. Double staining necessitated compensation for overlapping emission spectra by 
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electronic subtraction of any unwanted spectral “spillover” from the signal of interest. 
Simple stained infected erythrocytes (with Syto16 or annexin V-568) containing dye in the 
relevant concentrations were used as compensation controls for this multicolor study. 
To induce annexin binding according to Lang et al. (116), non-infected RBCs were 
incubated for 1 h at 37 °C with the Ca2+ ionophore ionomycin (0 and 1 µM, respectively) 
or oxidized by t-butylhydroperoxide (t-BHP, 1 mM for 15 min followed by 24h of post-
incubation) in a modified NaCl test solution consisting of ( in mM): 125 NaCl, 5 KCl, 5 D 
(+) glucose, 1 CaCl2, 1 MgSO4,  32 HEPES  titrated  to pH 7.4 with NaOH.   
2. 7. 4. Determination of intracellular Ca
2+ 
influx in the erythrocytes 
Fluo 3 acetoxymethyl AM ester was used as the fluorescent indicator. Fluo-3 (1- [2-amino-
5-(2,7-dichloro-6-hydroxy-3-oxo-9-xanthenyl) phenoxy] -2-(2-amino-5-methylphenoxy) 
ethane-N,N,N’,N’-tetra-acetic acid, C51H50C12N2O23 =1129.85) is a fluorescent cheater 
excited by visible light (~488nm), and emits a yellowish green fluorescence (~525nm) 
when bound to a calcium ion (198). The intensity of fluorescence depends on the free 
calcium concentration. Fluo-3 does not fluoresce unless bound to calcium ions. 
Intracellular Ca
2+ 
measurements were performed as described previously by Andrews et 
al., (2002) (206). Erythrocytes were loaded with fluo-3 AM (Calbiochem, Bad Soden, 
Germany) by addition of fluo-3 AM stock solution (2 mM diluted in DMSO) to 1 ml of 
erythrocyte suspension (0.16% hematocrit in Ringer solution; 4 µM fluo-3 AM final 
concentration). The cells were incubated at 37°C for 15 min under protection from light. 
An additional 2-µl aliquot of fluo-3 AM was added, and then the mixture was incubated for 
25 min. Fluo-3-loaded erythrocytes were centrifuged at 1,000 g for 5 min at 22°C and then 
washed twice with Ringer solution containing 0.5% bovine serum albumin (Sigma) and 
once with Ringer solution and incubated. For flow cytometry, fluo-3-loaded erythrocytes 
were re-suspended in 1 ml of Ringer solution (0.16% hematocrit) containing serial 
concentrations of amphotericin B or sodium butyrate
 
and incubated at 37°C for 30 min. As 
a positive control, erythrocytes were stimulated with 1 µM Ca
2+ 
ionophore ionomycin 
(Sigma) for 3 min prior to analysis to increase intracellular Ca
2+ 
activity. For negative 
control, cells were incubated for 30 min at 37°C with vehicle alone. Subsequently, Ca
2+
-
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dependent fluorescence intensity was measured in fluorescence channel FL-1 with an 
excitation wavelength of 488 nm and an emission wavelength of 530 nm (115). 
2. 7. 5. Measurement of hemolysis 
After incubation of infected erythrocytes for 48 hours at 37°C, the samples were 
centrifuged (3 min at 400 g, RT), and the supernatants were harvested. As a measure of 
hemolysis, the hemoglobin (Hb) concentration of the supernatants was determined 
photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in 
distilled water was defined as 100% hemolysis (207, 208) (Appendix-2 protocol 9). 
2. 7. 6. In vivo proliferation of P. berghei ANKA 
For infection of mice P. berghei ANKA-parasitized mouse erythrocytes (1x10
6
) were 
injected intraperitoneally (209) into sex- and age-matched mice fed on control diet and 
with free access to drinking water or 10% (w/w) GA dissolved in tap water (100 g/L) or 
amphotericin B (1.4 mg/kg body weight for three successive days after day 8) administered 
subcutaneously. Parasitemia was determined daily from the 8
th 
day of infection by flow 
cytometry. The blood samples were stained with Giemsa stain and the DNA/RNA-specific 
fluorescence dye Syto-16 and the Syto-16 fluorescence was analysed with a FACS Calibur 
cytometer (Becton Dickinson , Heidelberg, Germany) at fluorescence channel 1 (FL1 488 
nm excitation and 530 nm emission as described above). 
2. 7. 7. Measurement of the in vivo clearance of fluorescence-labelled erythrocytes 
Fluorescence-labelled erythrocytes from mice were obtained by staining erythrocytes with 
carboxyfluorescein diacetate, succinimidyl ester (CFSE) from Molecular Probes (Leiden, 
The Netherlands). The labelling solution was prepared by addition of adequate amounts of 
a CFSE stock solution (10 mM in DMSO) to phosphate-buffered saline (PBS) to yield a 
final concentration of 5 µM. Then, the cells were incubated with labelling solution for 30 
min at 37°C. The cells were pelleted at 1000 x g for 5 min, washed and re-suspended in 
fresh, pre-warmed PBS. The fluorescence-labelled erythrocytes were injected into the tail 
veins of mice. At indicated time points, blood was taken from the mice and CFSE-
dependent fluorescence intensity of the erythrocytes was measured in the fluorescence 
channel FL-1. The percentage of CFSE-positive erythrocytes was calculated in % of the 
whole population (169). 
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2. 7. 8. Measurement of the fluorescence-labelled erythrocytes in the spleens of mice 
The fluorescence-labelled erythrocytes were injected into the tail veins of mice. After 2 
hours the mice were sacrificed and the spleens were dissected and carefully mashed 
through a net. Finally, CFSE-dependent fluorescence intensity of the erythrocytes in spleen 
suspensions was measured in the fluorescence channel FL-1 (209). 
2. 7. 9. Data analysis and statistics  
Data are expressed as means ± SEM, and (n) represents the number of independent 
experiments. Statistical analysis was made by paired or unpaired t test or by ANOVA 
using Dunnett’s or Tukey’s test as post hoc test, where appropriate. P ≤ 0.05 was 
considered statistically significant. Statistical analysis was performed with GraphPad 
InStat version 3.00 for Windows (GraphPad Software, San Diego, CA; 
www.graphpad.com). 
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3. Results 
3. 1. Influence of amphotericin B on the course of malaria 
Effect of amphotericin B on in vitro growth of P. falciparum in human erythrocytes. 
In vitro growth of P. falciparum in human erythrocytes was significantly decreased at 
amphotericin B started from concentration of 0.01 µM (Fig. 3. 3). Within 48 hours the 
percentage of infected erythrocytes increased from 4 to 23%. Increased amphotericin B 
concentration decreases percentage parasitemia in a dosage dependant manner, an effect 
reaching statistical significance at ≥ 0.01 µM amphotericin B concentrations (p< 0.05). 
Effect of amphotericin B on P. falciparum DNA amplification 
Intraerythrocytic DNA amplification in erythrocytes was not significantly influenced by 
amphotericin B at the concentrations employed but only at the highest one (1µM). (Fig. 3. 
4). 
Effects of amphotericin B on erythrocytes hemolysis. 
At the applied concentrations amphotericin B did not disrupt the integrity of the cell 
membrane and did not induce significant hemolysis (Fig. 3. 5). 
Fluo 3 fluorescence intensity in control, ionophore ionomycin and amphotericin B treated 
erythrocytes 
Erythrocyte shrinkage induces activation of Ca
2+
-permeable non-selective cation channels. 
Thus erythrocytes were loaded with the Ca
2+
-sensitive fluorescence dye fluo-3 (2 µM fluo-
3 AM) to determine the effect of amphotericin B on cytosolic Ca
2+ 
activity. Cells were 
incubated in the absence or presence of amphotericin B
 
(1 µM for 30 min) or the Ca
2+ 
ionophore ionomycin (1 µM), and fluo-3 fluorescence intensity was monitored using 
FACS. As illustrated in Fig. 3. 6, amphotericin B increased fluo-3 fluorescence intensity. 
As a positive control, the Ca
2+ 
ionophore ionomycin (1 µM) similarly enhanced the fluo-3 
fluorescence intensity. The data strongly suggest that the observed amphotericin B effect 
on fluo-3-loaded erythrocytes reflect an increase in cytosolic free Ca
2+ 
concentration. 
Fluo 3 fluorescence intensity in control and amphotericin B treated erythrocytes 
Incubation of erythrocytes in Ringer solution with amphotericin B for 48 h indicates 
significant difference from the respective value of Fluo 3 fluorescence intensity in the 
absence of amphotericin B (Fig. 3. 7). Fluo3 fluorescence intensity increased by increased 
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amphotericin B concentration. It was found to be 19.73 (arb. units) in the absence of 
amphotericin B, increases in Fluo3 fluorescence reaching statistical significance at ≥ 0.1 
µM amphotericin B concentration (p< 0.01).. 
Effects of amphotericin B on phosphatidylserine exposure of P. falciparum infected and 
non-infected erythrocytes. 
To identify phosphatidylserine exposing erythrocytes, annexin V binding has been 
determined in FACS analysis. The percentage of annexin-binding erythrocytes was low in 
fresh erythrocytes (1.24 ± 0.24%, n = 6). Exposure of uninfected erythrocytes to 
amphotericin B-free Ringer solution increased the percentage of annexin binding cells 
within 24 h to 4.14 ± 0.50% (n = 6) (Fig. 3. 8 A). Infection of erythrocytes with P. 
falciparum significantly enhanced the percentage of annexin binding erythrocytes. 
Phosphatidylserine exposure of infected erythrocytes was augmented by amphotericin B, 
an effect reaching statistical significance at 0.01 µM amphotericin B (Fig. 3. 8 B).  
Effects of amphotericin B on forward scatter of infected and non-infected erythrocytes. 
Infection of human erythrocytes with P. falciparum induces a biphasic change of the host 
erythrocyte volume. In the early trophozoite stage infected cells loose KCl and water 
leading to cell shrinkage. In the present study, ring-stage-synchronized erythrocytes when 
grown for 48h re-invaded new erythrocytes in which the parasite at the early trophozoite 
stages. Accordingly, infected cells had a lower forward scatter than uninfected 
erythrocytes. Amphotericin B leads to farther significant decrease in infected erythrocyte 
volume illustrated in Fig. 3. 9 A & B, which shows decreased forward scatter. 
In vivo proliferation of P. berghei in control and amphotericin B treated mice. 
Further experiments were performed on the impact of amphotericin B treatment on the 
course of malaria infection in vivo. To this end mice were infected with P. berghei. As 
shown in Fig. 3. 10, parasitemia in control and amphotericin B mice was (2.61 ± 0.18 and 
2.33 ± 0.12%) respectively 8 days after infection but gradually increased in the next 12 
days. In untreated animals, the percentage of parasitized erythrocytes increased up to 50.36 
± 3.98%. The addition of 0.7 mg/kg b.w. amphotericin B had only a slight effect on 
parasitemia. Thus, the concentration of amphotericin B was increased to 1.4 mg/kg b.w., 
which indeed significantly blunted the increase of parasitemia compared to non treated 
animals to 39 ± 2.46 % (mean ± SEM, n = 6), (p<0.05) (Fig. 3. 11). 
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Clearance of amphotericin treated erythrocytes from circulating blood 
A next series of experiments explored, whether the enhanced phosphatidylserine exposure 
accelerates clearance of erythrocytes from circulating blood in vivo. For this purpose mice 
were either left untreated or treated with 1.4 mg/Kg b w amphotericin B intraperitoneally, 
their erythrocytes were labelled with the dye CFSE and injected into the tail vein. As 
illustrated in Fig. 3. 12 A, the clearance of erythrocytes in amphotericin B treated mice was 
slightly, but significantly faster than erythrocyte clearance in untreated mice. On the other 
hand, the fraction of labelled erythrocytes recovered in the spleen was significantly 
enhanced by amphotericin B treatment (Fig. 3. 12 B). 
The effect of amphotericin B on survival of P. berghei infected mice. 
The effect of amphotericin B on the parasitemia was paralleled by enhanced survival of the 
amphotericin B treated animals. Whereas all untreated animals died within 27 days after 
the infection, 80% of the amphotericin B treated animals survived the infection for more 
than 27 days (Fig. 3. 13). Thus, amphotericin B treatment indeed significantly modified the 
course of malaria. 
3. 2. Influence of butyrate and gum Arabic on the course of malaria 
Effect of butyrate on in vitro growth of P. falciparum in human erythrocytes. 
The influence of butyrate on the in vitro growth of the parasite was analyzed. P. 
falciparum-infected erythrocytes were cultured in human erythrocytes and synchronized to 
ring stage by sorbitol treatment. Within 48 hours the percentage of infected erythrocytes 
increased from 5 to 26 %. Increased butyrate concentration decreases percentage 
parasitemia in a dosage dependant manner, an effect reaching statistical significance at ≥ 
0.5 mM butyrate concentration (Fig. 3. 14) (p< 0.05). 
Effect of butyrate on P. falciparum DNA amplification. 
To test for intraerythrocytic DNA amplification infected erythrocytes were ring-stage 
synchronized and cultured for further 24h. As a result of increased butyrate concentration, 
statistically significant decrease in DNA amplification was observed only at the highest 
concentration (10 mM) (Fig. 3. 15). 
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Effect of butyrate on erythrocytes cytosolic Ca2+ concentration. 
Activation of cation channels is expected to increase cytosolic Ca2+ activity. Fluo3 
fluorescence was employed to test, whether butyrate modifies the cytosolic Ca2+ 
concentration. As illustrated in Fig. 3. 16, 48 hours incubation of erythrocytes in the 
presence of different concentrations of amphotericin B was followed by a significant 
increase in Fluo3 fluorescence. Accordingly, exposure to amphotericin B increases 
cytosolic Ca2+ activity of human erythrocytes. 
Effects of butyrate on phosphatidylserine exposure of infected and non-infected 
erythrocytes. 
To determine the effect of infection and butyrate on suicidal erythrocyte death (eryptosis), 
the percentage of phosphatidylserine-exposing erythrocytes was estimated by measurement 
of annexin V-binding in FACS analysis. Prior to the infection the percentage of annexin V-
binding erythrocytes was low (1.2 ± 0.11%, n = 6). Within 24 hours, infection with P. 
falciparum markedly increased annexin V-binding of infected erythrocytes compeered to 
non infected mean ± SEM, (26.5 ± 4.3 and 15.9 ± 3.2) respectively (p≤0.05; paired 
ANOVA). Both in the absence and presence of butyrate the percentage of annexin V-
binding was significantly higher in infected than non-infected erythrocytes. The 
phosphatidylserine exposure of infected erythrocytes was significantly increased by 
increased butyrate concentration, an effect reaching statistical significance at 5 mM 
butyrate (p≤0.05; paired ANOVA) (Fig. 3. 17). 
Effects of butyrate on forward scatter of infected and non-infected erythrocytes. 
At early stages of the parasite development, infection of erythrocytes decreased erythrocyte 
forward scatter, pointing to cell shrinkage. At late stages of the parasite development 
(trophozoites), infection increased the forward scatter, pointing to cell swelling. Butyrate 
decreased the forward scatter of the early and late stage infected erythrocytes. Fig. 3. 18 A 
& B shows significant difference (p < 0.05) from absence of butyrate at early stages, and 
also indicates significant difference to non-infected erythrocytes (p < 0.05). 
In vivo effect of gum Arabic on parasitemia of P. berghei infected mice. 
To determine the in vivo efficacy of gum Arabic, mice were infected with P. berghei with 
or without gum Arabic treatment. Gum Arabic (10 % in drinking water) was administered  
52 
 
 
from the 8th day of infection, when parasitemia was still low in control and infected mice, 
mean ± SEM, (3.44 ± 0.63 and 5.09 ± 0.21%) respectively, no significant deferens was 
observed. The percentage of infected erythrocytes increased gradually in mice without or 
with gum Arabic treatment reaching 43.6 ± 4.39 and 58.08 ± 3.03 respectively at day 21 
(Fig. 3. 19). However, the percentage of parasitized erythrocytes was slightly lower in gum 
Arabic-treated mice than in mice without gum Arabic treatment, an effect reaching 
statistical significance between day 16 to day 20 of infection (p≤0.05; paired ANOVA) 
(Fig. 3. 19). 
Effects of gum Arabic on survival of P. berghei infected mice. 
The treatment with gum Arabic further influenced the survival of P. berghei-infected mice. 
As shown in Fig. 3. 20, all of the gum treated animal survived up to day 21 after the 
infection, were the untreated animals number decreased by 30 %. All of the untreated 
animals died within 26 days after the infection. In contrast as many as 70% of the gum 
Arabic-treated animals survived the infection for more than 26 days. 
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Fig. 3. 3: In vitro growth of Plasmodium falciparum in human erythrocytes as a function of 
amphotericin B concentration. 
Arithmetic means ± SEM (n = 8) of in vitro growth of Plasmodium falciparum in human 
erythrocytes as a function of amphotericin B concentration. *, **Indicates significant difference (p 
< 0.05; p < 0.01) from absence of amphotericin B. 
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Fig. 3. 4: DNA amplification of Plasmodium falciparum in human infected erythrocytes as a 
function of amphotericin B concentration (arithmetic means ± SEM, n = 8). *Indicates 
significant difference (p < 0.05;) from absence of amphotericin B. 
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Fig. 3. 5: Effect of amphotericin B on erythrocyte membrane integrity. Arithmetic 
means ± SEM (n= 4) of the percentage of haemolysed erythrocytes exposed for 48 hours to 
Ringer solution without (white bar) or with (black bars) amphotericin B at the indicated 
concentrations. 
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Fig. 3. 6: Effect of amphotericin B and ionomycin cytosolic fluo-3 fluorescence 
intensity in non-infected erythrocytes. Mean Ca
2+
-sensitive fluo-3 fluorescence 
(arithmetic means ± SE; n = 6) of erythrocytes incubated either in Ringer solution 
(Control) or in Ringer solution containing amphotericin B
 
(1 µM) or ionomycin (1 µM). * 
Indicates significant difference (p < 0.05) from control. 
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Fig. 3. 7: Effect of amphotericin B on cytosolic Ca2+ concentration in non-infected 
erythrocytes. Arithmetic means ± SEM (n = 6) of the geo. means of Fluo3 fluorescence in 
erythrocytes exposed for 48 hours to Ringer without (white bar) or with (black bars) different 
concentrations of amphotericin B . ** (p<0.01) indicates significant difference from the respective 
value in the absence of amphotericin B. 
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Fig. 3. 8 A & B: Annexin binding of non-infected and Plasmodium falciparum infected 
erythrocytes from control and amphotericin B treated samples. A) Arithmetic means ± 
SEM (n = 4) of annexin binding to erythrocytes in freshly drawn blood (open bar) and 24 
hour after incubation in RPMI 1640 medium containing 0.05 µM amphotericin B (closed 
bar) #Indicates significant difference between two groups(p ≤ 0.01). B) Arithmetic means ± 
SEM (n = 4) of annexin binding of infected (closed bar) and non-infected (open bar) 
erythrocytes before and after treatment with different concentrations of amphotericin B. 
*Indicates significant difference (p < 0.05) to non-infected erythrocytes. 
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Fig. 3. 9 A & B: Effects of amphotericin B on forward scatter of Plasmodium 
falciparum infected and noninfected erythrocytes. A). Arithmetic means ± SEM (n = 6) 
forward scatter of the early stage-infected erythrocytes (closed symbols) and non-infected 
(open symbols) erythrocytes as a function of the butyrate concentration. * indicates 
significant difference (p≤0.05; ANOVA) from absence of butyrate, # indicate significant 
difference (p≤0.05; ANOVA) from non-infected erythrocytes. B). Arithmetic means ± 
SEM (n = 6) forward scatter of late stage-infected erythrocytes (closed symbols) and non-
infected (open symbols) erythrocytes as a function of the butyrate concentration. * 
indicates significant difference (p≤0.05; ANOVA) from absence of butyrate. # indicates 
significant difference to non-infected erythrocytes. 
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Fig. 3. 10: Effect of amphotericin B treatment on parasitemia of Plasmodium berghei 
infected mice: Original histograms of parasitemia-dependent Syto 16 fluorescence in 
untreated animals (upper panels) and animals treated from day 8 until day 20 with 1.4 mg 
amphotericin B intraperitoneally (lower panels) 10 (left panels) and 20 (right panels) days 
after infection with P. berghei.  
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Fig. 3. 11: Effect of amphotericin B on parasitemia of P. berghei infected mice. 
Arithmetic means ± SEM (n = 6) of parasitemia in mice without treatment (open circles) or 
treated with amphotericin B (closed circles) as a function of days after infection with P. 
berghei. * indicates significant difference (p ≤ 0.05) from iron replete animals. 
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Fig. 3. 12 A & B: In vivo clearance of fluorescence labelled erythrocytes from 
circulating blood. Disappearance of CFSE labelled non infected and infected mouse 
erythrocytes from circulating blood following injection into the tail vein of untreated and 
amphotericin B (1.4 mg i.p.) treated mice. A): Arithmetic means ± SEM (n = 6) of the 
percentage of CFSE-labelled non-infected erythrocytes in circulating blood of untreated 
(open symbols) or amphotericin B (closed symbols) treated animals. * indicates significant 
difference (p<0.05) from untreated animals. B): Abundance of CFSE labelled untreated 
(open bar) or amphotericin B treated (closed bar) erythrocytes in spleen. Arithmetic means 
± SEM (n=6). *indicates significant difference from the untreated animals. 
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Fig. 3. 13: Effect of amphotericin B on survival of P. berghei infected mice. Arithmetic 
means ± SEM (n = 6) represent survival of mice without treatment (open circles) or treated 
with amphotericin B
 
(closed squares) as a function of days after infection with P. berghei. 
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Fig. 3. 14: In vitro growth of P. falciparum in human erythrocytes as a function of 
butyrate concentration (arithmetic means ± SEM, n = 8). *, ** indicates significant 
difference (p≤0.05, p≤0.01) from absence of butyrate. 
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Fig. 3. 15: Intraerythrocytic DNA amplification of P. falciparum in human 
erythrocytes as a function of butyrate concentration (arithmetic means ± SEM, n = 6). * 
indicates significant difference (p≤0.05) from absence of butyrate. 
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Fig. 3. 16: Effect of butyrate on cytosolic Ca2+ activity in non-infected erythrocytes. Arithmetic 
means ± SEM (n = 6) of the geometric means of Fluo3 fluorescence in erythrocytes exposed for 48 
hours to Ringer without (white bar) or with (black bars) different concentrations of butyrate. * 
(p<0.05) indicates significant difference from the respective value in the absence of butyrate. 
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Fig. 3. 17: Effects of butyrate on phosphatidylserine exposure of infected and non-
infected erythrocytes. Arithmetic means ± SEM (n = 6) of annexin V-binding of infected 
(closed bars) and non-infected (open bars) erythrocytes following infection of human 
erythrocytes with P. falciparum at 0 mM (left bars) and 10 mM butyrate. * indicates 
significant difference (p≤0.05; paired ANOVA) from non-infected erythrocytes, # 
*Indicates significant difference (p < 0.05) from absence of butyrate  
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Fig. 3. 18 A & B: Effects of butyrate on forward scatter of infected and non-infected 
erythrocytes. A): Arithmetic means ± SEM (n = 4) of forward scatter of the early stage-
infected erythrocytes (closed symbols) and non-infected (open symbols) erythrocytes as a 
function of the butyrate concentration. *Indicates significant difference (p < 0.05) from 
absence of butyrate, #Indicates significant difference to non-infected erythrocytes. B): 
Arithmetic means ± SEM (n = 4) of forward scatter of late stage-infected erythrocytes 
(closed symbols) and non-infected (open symbols) erythrocytes as a function of the 
butyrate concentration. *Indicates significant difference (p < 0.05) from absence of 
butyrate, #Indicates significant difference to non-infected erythrocytes. 
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Fig. 3. 19: Parasitemia of Plasmodium berghei infected mice. Arithmetic means ± SEM of 
parasitemia in mice without treatment (open circles, n = 8) or with 10 mg/kg B. W. of gum Arabic 
(closed circles, n = 6) as a function of days after infection with Plasmodium berghei. *Indicates 
significant difference from the untreated animals.  
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Fig. 3. 20: Effect of gum Arabic treatment on survival of Plasmodium berghei infected mice. 
Survival of mice without treatment (open circles) or with 10 % gum Arabic in drinking water 
(closed squares) as a function of days after infection with Plasmodium berghei. 
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4. Discussion 
Over the past centuries malaria, has been the major cause of morbidity and mortality 
among the mankind. As the time passed the pathogens coevolved with their hosts, 
simultaneously manipulating the hosts defence mechanisms by intruding and mimicking 
various host related metabolic and signalling pathways. In the course of their parasitic 
effect they modified themselves to proliferate and destruct the host to death. The present 
strategy for controlling and curing infectious diseases has targeted various metabolic or 
enzymatic systems within the parasite. The most severe drawback of this kind of 
controlling the diseases has lead to the development of parasitic resistance and consequent 
relapse of once-contained infectious diseases amidst the host. This study intended for a 
novel drug discovery in order to prevent the pathogen related resistance focusing on 
identifying and targeting host factors essential for pathogen entry, survival and 
proliferation. The innovative methods involved stimulation of the infected erythrocytes and 
recognition by the spleen macrophages to get rid of the pathogen and prevent the further 
course of the disease. 
Malaria pathogen, Plasmodium, enters erythrocytes and thus escapes recognition by the 
immune system. The pathogen induces oxidative stress to the host erythrocyte, which 
triggers eryptosis, the suicidal death of erythrocytes (167, 178). Eryptosis is characterized 
by cell shrinkage, membrane blebbing and cell membrane phospholipids scrambling with 
phosphatidylserine exposure at the cell surface. Phosphatidylserine-exposing erythrocytes 
are identified by macrophages which engulf and degrade the eryptotic cells. To the extent 
that infected erythrocytes undergo eryptosis prior to subsequent infection of other 
erythrocytes by Plasmodia, hence, the premature eryptosis may protect against malaria. 
Accordingly, any therapeutic intervention accelerating suicidal death of infected 
erythrocytes has the potential to foster elimination of infected erythrocytes, delay the 
development of parasitemia and favourably influence the course of malaria. 
Observations of this study indicate that Plasmodium infected erythrocytes can be targeted 
for induction of eryptosis in vitro and in vivo. This accelerated eryptosis of Plasmodium-
infected erythrocytes results in rapid clearance of infected erythrocytes and confers 
protection against severe course of malaria. Plasmodium imposes oxidative stress to the 
host cell leading to cation channel activation and Ca
2+ 
entry (210, 211). Thus, infection was 
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expected to trigger phosphatidylserine exposure. Infection of erythrocytes with 
Plasmodium was indeed found to trigger eryptosis (135). If the stimulation of eryptosis 
remains an abated, it may proceed too fast for the pathogen to allow intraerythrocytic 
maturation.  
4. 1. Influence of amphotericin B on the course of malaria 
According to the present observations, amphotericin B in different concentration exerted 
an inhibitory effect on intraerythrocytic P. falciparum proliferation in vitro.(Fig. 3. 3) 
Moreover, presence of amphotericin B further decreased the intraerythrocytic DNA 
amplification of the parasite, an effect reaching statistical significance only at the highest 
concentration in the experiment (Fig. 3. 4). In theory, the positive effect of amphotericin B 
treatment could have been due to amphotericin B induced lysis of the trophozoite stage of 
P. falciparum ](212). However, at the applied concentrations in this study, amphotericin B 
did not disrupt the integrity of the cell membrane and did not induce significant hemolysis 
(Fig. 3. 5). The concentrations required to elicit eryptosis are well within the range of those 
reached under treatment with amphotericin (213, 214). Eryptosis clearly exceeds hemolysis 
and thus, the observed phosphatidylserine exposure is not secondary to hemolysis. Higher 
levels of hemolysis have been reported earlier following exposure of erythrocytes to 
amphotericin B formulations (215). 
P. falciparum survival depends on the activation of several ion channels in the erythrocyte 
cell membrane, as they allow the uptake of nutrients, Na
+
 and Ca
2+
 and the disposal of 
waste products  (172). Increases in cytosolic Ca2+ activity is one of the major stimulators of 
eryptosis, which leads to cell membrane vesiculation, stimulates cell membrane scrambling 
and activates the cysteine endopeptidase calpain, an enzyme degrading the cytoskeleton 
and thus causing cell membrane blebbing (216). Ca
2+
 may enter through non-selective 
cation channels (132). The molecular identity of those channels is incompletely understood 
but may include transient receptor potential channels (TRPC6). The cation channels are 
activated by osmotic shock, oxidative stress and Cl- removal (134). 
In this study to determine the effect of amphotericin B on cytosolic Ca
2+ 
activity, cells 
were incubated in the absence or presence of amphotericin B or the Ca
2+ 
ionophore 
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ionomycin, and fluo-3 fluorescence intensity was monitored using FACS. As illustrated in 
Fig. 3. 6, amphotericin B
 
indeed increased fluo-3 fluorescence intensity. As a positive 
control, the Ca
2+ 
ionophore ionomycin similarly enhanced the fluo-3 fluorescence 
intensity. The data strongly suggest that the observed amphotericin B effect on fluo-3-
loaded erythrocytes reflect an increase in cytosolic free Ca
2+ 
concentration. Moreover, 
amphotericin B farther increased fluo-3 fluorescence intensity in a dose dependant manner 
(Fig. 3. 7). These results were in line with studies by Lang et al, which demonstrated the 
effect of amphotericin B on cytosolic free Ca2+  (205, 208). 
An increase in cytosolic Ca2+-activity is expected to stimulate cell membrane scrambling 
with phosphatidylserine exposure, which could be quantified by determination of annexin 
V-binding. As shown in Fig. 3. 8 A, the percentage of phosphatidylserine-exposing 
erythrocytes was low in the absence of amphotericin B. Exposure of erythrocytes for 48 
hours to Ringer solution containing amphotericin B (0.1 µM) was followed by a significant 
increase in annexin V-binding. Phosphatidylserine exposure was used as indicator of 
apoptosis (217). In this study amphotericin B was found to increase the percentage of 
annexin V binding which indicate phosphatidylserine exposure. As shown in Fig. 3. 8 B. 
Furthermore, the effect was particularly prominent in infected erythrocytes. Thus, 
amphotericin B preferably triggered phosphatidylserine exposure of infected cells.  
Infection of human erythrocytes with P. falciparum induces a biphasic change of the host 
erythrocyte volume. In the early trophozoite stage infected cells loose KCl and water 
leading to cell shrinkage. An increase in cytosolic Ca
2+ 
activity is further expected to 
induce cell shrinkage, which should be reflected by a decrease of forward scatter in FACS 
analysis. Amphotericin B further decreased forward scatter pointing to cell shrinkage, the 
effect which is more prominent in early stages P. falciparum infected erythrocytes (Fig. 3. 
9 A & B). The present experiments confirm the ability of amphotericin B to induce 
eryptosis (207). The decrease in forward scatter during eryptosis is paralleled by a decrease 
of packed cell volume and thus indeed reflects cell shrinkage (218). It was early shown 
that, the decrease in forward scatter is reversed by increased extracellular K+ concentration, 
which dissipates the chemical driving force for K+ exit. The decrease in forward scatter is 
further blunted by inhibitors of Ca2+-sensitive K+ channels. Thus the decrease in forward 
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scatter following entry of Ca2+ is most likely due to activation of Ca2+-sensitive K+ 
channels, with subsequent exit of K+, hyperpolarization, and exit of Cl– and H2O (144). 
The ability of amphotericin B to trigger scrambling of the cell membrane is shared by 
several amphiphiles (219). 
Obviously, increasing cytosolic Ca2+ concentrations leads to erythrocyte hyperpolarization, 
and activation of Ca2+-sensitive K+ channels (Gardos channels). The parallel stimulation of 
erythrocyte scramblase and Ca2+-sensitive K+ channels by an increase of cytosolic Ca2+ 
activity presumably serves to circumvent hemolysis of defective erythrocytes. Leakage of 
the cell membrane or impairment of Na+-K+-ATPase is expected to result in gain of NaCl, 
cell swelling, and, eventually, cell lysis (220). Even in normal erythrocytes, cytosolic Cl- 
activity is high, and the potential difference across the cell membrane is low. Thus the gain 
of Na+ and loss of K+ must be excessive to compromise volume constancy. Prior to that the 
leaky cell membrane increases cytosolic Ca2+ activity which activates the erythrocyte 
scramblase, leading to breakdown of phosphatidylserine asymmetry. The 
phosphatidylserine-exposing erythrocytes are detected by the macrophages and, thus, 
cleared from the circulation before hemolysis. The parallel activation of the Ca2+-sensitive 
K+ channels, hyperpolarization, and cellular loss of K+ and Cl- counteract cell swelling and, 
thus, may serve to prevent premature lysis of the erythrocytes (114). 
The treatment of P. berghei infected mice with amphotericin B significantly decreased the 
development of in vivo parasitemia (Fig. 3. 10 & 3. 11). The effect is presumably due to 
premature phosphatidylserine exposure of infected cells. In vitro, phoshpatidylserine 
exposure does not lead to sequestration and clearance of erythrocytes and thus does not 
significantly modify the increase of parasitemia. Amphotericin B treated 
phosphatidylserine exposing erythrocytes are rapidly cleared from circulating blood. In 
nucleated cells amphotericin B has been demonstrated to enhance the cation conductance 
in the plasma membrane (221) with subsequent Na+ entry and increase in the intracellular 
Ca2+ concentration (222). It has further been shown to trigger a signaling cascade involving 
TLR-2, Btk, PLC, PKC, c-Src and NF-kappaB (223, 224). 
A next series of experiments explored, whether the enhanced phosphatidylserine exposure 
accelerates clearance of erythrocytes from circulating blood in vivo. For this purpose mice 
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were either left untreated or treated with 1.4 mg/Kg b. w. amphotericin B., their 
erythrocytes were labelled with the dye CFSE and re-injected into the tail vein. As 
illustrated in Fig. 3. 12 A, the clearance of erythrocytes in amphotericin B treated mice was 
slightly, but significantly faster than erythrocyte clearance in untreated mice. Most 
importantly, the decline was particularly fast in infected CFSE-labelled erythrocytes (Fig. 
3. 12 A). On the other hand, the majority of cleared labelled cells were accumulated in the 
spleen (Fig. 3. 12 B).  
Decreased in vivo parasitemia following amphotericin B treatment may be expected to 
affect the survival of infected animals. Similar to previous report (212), none of the 
untreated mice survived the infection with P. berghei (Fig. 3. 13). In contrast, 80 % of the 
amphotericin B
 
treated mice were still alive 28 days after the infection illustrating that 
amphotericin B
 
treatment indeed favourably modifies the course of malaria. 
4. 2 Influence of butyrate and gum Arabic on the course of malaria 
In the other part of this study butyrate in different concentrations inhibited the proliferation 
of P. falciparum in a dosage dependant manner (Fig. 3. 14). This effect is most probably 
due to the activity of butyrate as histone deacetylase inhibitor reported by Davie 
2003.(225). Andrews et al reported the antimalarial activity of histone deacetylase 
inhibitors and cyto-differentiating agents in vitro and in vivo (226). Histones are nuclear 
core proteins act as spools around which DNA winds, they play an important role in 
transcriptional regulation through the continuous acetylation/deacetylation of the έ-amino 
group of specific lysine residues (225). Evert et al (2006) reported that butyrate alter gene 
expression and arrest cell proliferation by inhibition of the chromatin-remodelling activity 
of histone deacetylases (HDAC) (227). Interestingly, butyrate inhibitory action of HDAC 
activity was found to affect the expression of only 2% of genes (225). The findings of this 
study were in parallel with that, as butyrate exerted very mild effects on P. falciparum 
DNA amplification only at highest concentrations (10 mM) (Fig. 3. 15). Butyrate farther 
increased fluo-3 fluorescence intensity in a dose dependant manner (Fig. 3. 16). Increased 
fluo 3 fluorescence intensity was found to be directly proportional to cytosolic Ca2+ 
concentration (207). 
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On the other hand, the presence of butyrate
 
significantly increased the percentage of 
annexin V binding erythrocytes. The effect was particularly prominent in infected 
erythrocytes (Fig. 3. 17). Thus, butyrate
 
preferably triggered phosphatidylserine exposure 
of infected cells. The specific binding of annexin V to phosphatidylserine has greatly 
facilitated the measurement of the exposure of small amounts of this phospholipid on the 
outer membrane of cells. Annexin V can be labelled with a fluorescent compound; this will 
make it possible to use a flow cytometer to estimate the percentage of erythrocytes with 
phosphatidylserine exposed on their outer surface. Several lines of evidence reported by a 
number of investigators indicated that exposure of phosphatidylserine on the cell surface is 
a general feature of apoptosis and suicidal erythrocyte death (eryptosis) (228, 229). As 
shown earlier (179, 230), eryptosis is further stimulated by P. falciparum infection. 
Intraerythrocytic Plasmodia impose oxidative stress to the host cell, which in turn activates 
the Ca2+ permeable cation channels (231). The following Ca2+ entry leads to stimulation of 
cell membrane scrambling (232). 
Butyrate further decreased forward scatter pointing to cell shrinkage (Fig. 3. 18), which 
was presumably due to increase of cytosolic Ca
2+ 
activity, activation of Ca
2+ 
sensitive K
+ 
(GARDOS) channels (144), K
+ 
exit, hyperpolarization of the erythrocyte membrane 
potential and Cl
- 
exit (143). The exit of KCl is followed by osmotically obliged water and 
thus leads to cell shrinkage (170). The volume regulatory cation channels are not only 
expressed in erythrocytes but in several nucleated cells (233). As an increase of cytosolic 
Ca2+ could similarly induce apoptotic cell death in nucleated cells, activation of the volume 
regulated cation channels could similarly participate in the triggering of apoptosis in 
anucleated cells exposed to an osmotic shock (234, 235). 
The present study reveals a completely novel effect of gum Arabic on the course of 
malaria. Following infection with P. berghei the increase of parasitemia was significantly 
less rapid in gum Arabic treated mice than in untreated mice (Fig. 3. 19). Moreover, gum 
Arabic significantly increased the survival of P. berghei infected mice. Similar to what has 
been shown earlier (210), untreated mice all die from infection with P. berghei at day 26. 
In contrast, 70% of the gum Arabic treated mice survived up to day 26 following infection 
(Fig. 3. 20). Thus, gum Arabic treatment favourably modifies the course of malaria.  
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The present observations provide some hints to mechanisms underlying the beneficial 
effect of gum Arabic treatment. It is well-known that gum Arabic is fermented by intestinal 
bacteria, leading to the formation of various degradation products such as short-chain fatty 
acids as butyrate which is important (236). In a recent study, serum butyrate concentrations 
were increased after treatment with gum Arabic in healthy subjects (237). Moreover, 
butyrate compounds have been shown to up regulate the formation of fetal haemoglobin 
(238), which may in turn confer some protection against a severe course of malaria. 
Specifically, fetal haemoglobin has been shown to delay the haemoglobin degradation and 
thus to impede the intraerythrocyte growth of Plasmodium (239). 
Gum Arabic could have affected parasitemia and host survival by increasing butyrate 
levels, which is known to delay the intraerythrocyte growth of the parasite by its is effects 
as inhibitor of histone deacetylase activity, or alternatively by increasing the erythrocyte 
content of fetal haemoglobin, which is also known to delay the intraerythrocyte growth of 
the parasite (239). Gum Arabic, butyrate and/or fetal hemoglobin may affect parasitemia 
and host survival by accelerating the eryptosis of infected erythrocytes (240). 
Phosphatidylserine-exposing erythrocytes are phagocytosed and thus rapidly cleared from 
circulating blood (241). 
One of the important results of this study is the prominent effects of amphotericin B and 
butyrate/or gum Arabic in increasing erythrocytes cytosolic Ca2+. Increased cytosolic Ca2+ 
is crucial factor for stimulation of eryptosis (175). Eryptosis is triggered by redox-
sensitive, Ca2+ permeable, non-selective cation channels, activation of the Gardos K+ 
channel and cell shrinkage. 
Infection with P. falciparum is expected to increase the cytosolic Ca2+ activity and thus to 
induce eryptosis as a result of non selective cation channels stimulation. Most probably, 
the parasite utilizes these Ca2+ permeable non-selective cation channels to adapt the ionic 
composition of the host cytosol to its needs(175). However, most of the Ca2+ entering the 
parasitized erythrocyte is either extruded across the host cell membrane or taken up by the 
pathogen ‘‘buffering’’ so that cytosolic Ca2+ activity remains low. Buffering of the 
cytosolic Ca2+ by the parasite probably prevents Gardos K+ channel activation and 
substantial host cell shrinkage during early parasite development. Hence, in addition to its 
78 
 
effect on parasite growth, the infection-induced Ca2+-permeable NSC conductance 
mediates at least in part the reported transiently elevated free Ca2+ concentration in the host 
cytosol Ca2+ (127, 242). Possibly in synergy with oxidative stress, the elevated cytosolic 
Ca2+ in turn triggers breakdown of the phospholipid asymmetry of the host cell membrane 
at mature parasite stages (243). Phosphatidylserine scrambling occurs especially under 
conditions of high parasitemia, which is associated with increased oxidative stress and 
ATP depletion (244). 
Phosphatidylserine is present only in small amounts in the outer leaflet of fresh 
erythrocytes (245). This is consistent with the low annexin-binding, i.e. in principle 
phosphatidylserine exposure, observed in non-infected control co-cultured erythrocytes in 
the present study. Phosphatidylserine exposure increases progressively on erythrocytes 
when treated with the Ca2+ ionophore ionomycin (122). This is consistent with the present 
measurements: erythrocytes treated with the Ca2+ ionophore ionomycin showed a high 
degree of phosphatidylserine exposing erythrocytes. The phosphatidylserine exposure 
observed in ionomycin-treated erythrocytes might be the result of the synergistic action of 
the two known eryptosis signaling pathways: the increase in cytosolic Ca2+ per se activates 
the scramblase and inhibits the translocase. Moreover, the Gardos effect activates the 
sphingomyelinase that results in ceramide formation, which further stimulates the 
scramblase. 
Early the exposure of phosphatidylserine at the outer surface of the cell membrane is 
presumably followed by binding to phosphatidylserine receptors on macrophages and 
subsequent phagocytosis of the affected erythrocyte. The lysosomal degradation may 
eventually eliminate the pathogen (246). Macrophages that phagocytose ring-stage infected 
erythrocytes are less intoxicated by hemozoin as opposed to those phagocytose late-stage 
infected erythrocytes. Plasmodium parasites detoxify the free heme of digested 
hemoglobin as polymerized ß-hematin (the pigment hemozoin) in their food vacuoles. 
Ingestion of late-trophozoite infected erythrocytes with a high amount of hemozoin by 
phagocytes alters the function of macrophages, monocytes and dendritic cells (247). 
Moreover, hemozoin-macrophage interactions impair migration of macrophages and 
contribute to the cytokine-mediated pathology of malaria (248, 249).  
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Erythrocytes with haemoglobinopathies or G6PD-deficiency are highly prone to enter 
eryptosis (158) and pharmacological induction of phosphatidylserine exposure of ring 
stage-infected erythrocytes reportedly accelerates their clearance. Thus, manoeuvres 
accelerating eryptosis by administration of amphotericin B or gum Arabic may result in 
premature clearance of the intraerythrocytic parasite. As a matter of fact, iron deficiency, 
lead, chlorpromazine, inhibition of NO synthase by L-NAME, azathiopring, amiodarone, 
and aurothiomalate (179, 180, 200, 250, 251), decrease parasitemia and partially enhance 
the survival of Plasmodium berghei-infected mice eventually by accelerating erythrocyte 
death. Thus, several conditions are known, which are associated with enhanced 
susceptibility to eryptosis and at the same time with a milder course of malaria. Among 
those, sickle cell trait is an example of a condition which is not associated with the 
problem of developing resistance of the pathogen. 
Conclusion 
In conclusion amphotericin B and gum Arabic stimulate the erythrocytic machinery 
responsible for the eryptosis following infection with Plasmodium. The acceleration of 
eryptosis precedes the full intraerythrocytic maturation of the pathogen, thus prevents the 
further lethal course of the disease and fosters host survival during malaria. The revelations 
defend that the stimulation of eryptosis in infected erythrocytes is a host dependent 
mechanism to combat against infection. The experimental results not only justify that the 
stimulation of eryptosis in infected erythrocytes is not only a host dependent defence 
mechanism but also a novel approach to prevent the chances of resistance in plasmodia. 
80 
 
 
Recommendation 
1. This method of identifying new host mediated antimalarial agents may be 
combined with the regular antimalarial agents with host directed drug therapy and 
increase the efficacy in eliminating the invaded and invading pathogen, thus control 
the resurgence of once contained disease. 
2. Amphotericin B and gum Arabic was found to blunts the parasitaemia and leads to 
a favourable course of malaria. Further studies are needed to explore the additional 
mechanisms behind these beneficial antimalarial activity. 
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Appendix I 
Laboratory chemicals 
Acetic acid (100%, glacial)   Merck Eurolab GmbH 
Adenine      Sigma, Deisenhofen  
Agarose     Carl Roth, Karlsruhe 
Azure B     Sigma-Aldrich, Taufkirchen 
Albumax II      Gibco-Invitrogen, Karlsruhe 
Annexin V-FLUOS     Boehringer, Mannheim 
Annexin V-568     Roche, Mannheim 
Amphtericin B    Sigma, Deisenhofen 
t-butylhydroperoxide  (8 M)   Sigma, Deisenhofen 
CaCl2       Sigma, Deisenhofen 
Cardiolipin (from bovine heart)   Sigma, Munich 
Citrate-Phosphate-Dextrose-Stabiliser Baxter S.A. (Fenwal), Maurepas, France 
DETAPAC (C14H23N3O10)   Sigma (Fluka), Munich 
Dextrose monohydrate (D (+) glucose)  Sigma, Deisenhofen 
DL-Dithiothreitol (DTT) minimum 99 % Sigma, Deisenhofen  
2,4 –Dichloroisocoumarin    Biomol GmbH, Hamburg 
Dipotassium hydrogen phosphate   Merck KGaA, Darmstadt 
Dimethylsulfoxid (DMSO)    Sigma, Deisenhofen 
Disodium hydrogen phosphate anhydrous     Merck KgaA, Darmstadt 
EDTA       Sigma, Steinheim 
Ethanol      Merck Eurolab, Darmstadt 
Ethidium bromide (10 mg/ml)  Carl Roth, Karlsruhe 
Fluo-3/AM      Calbiochem, Bad Soden 
Gas mixture (90% N2 / 5% O2 / 5% CO2)  Hoepfner, Reutlingen; Mast, Tuebingen 
Gentamicin sulphate     Gibco InVitrogen, Karlsruhe 
Glutamine      Gibco InVitrogen, Karlsruhe 
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Giemsa staining solution     Sigma, Deisenhofen 
Glycerol     Sigma-Aldrich, Taufkirchen 
Gum Arabic     Dar Savana, Sudan 
HCL       Merck Eurolab, Darmstadt 
HEPES      Sigma, Deisenhofen 
HEPES/NaOH 1M solution   Sigma, Deisenhofen 
Hypoxanthine      Sigma, Deisenhofen 
Ionomycin       Sigma, Munich 
Immersion oil Type A    Cargille Laboratories, Cedar Grove, NJ, USA 
Inosine     Sigma-Aldrich, Taufkirchen 
Instamed RPMI 1640 with Glutamine Gibco Invitrogen, Karlsruhe 
Isopropanol      Merck Eurolab, Darmstadt 
KCl       Sigma, Deisenhofen 
Mannitol      Sigma, Deisenhofen 
Methanol      Merck KgaA, Darmstadt 
Methylene blue    Sigma-Aldrich, Taufkirchen 
Multi Twist Top Vials 1.7 ml   Roth, Karlsruhe 
Multi Twist Top Vial Caps   Roth, Karlsruhe 
NaCl       Sigma, Deisenhofen 
Na-gluconate      Sigma, Deisenhofen 
NaHCO3     Sigma, Deisenhofen 
NaOH                                                             Sigma Diagnostics, St Louis, MO, USA 
Na-vanadate     Sigma-Deisenhofen 
Nitrogen (Gas)    Mast, Tuebingen 
NMDG-Cl      Sigma, Deisenhofen 
n-octylglucopyranoside (C14H28O6)  Sigma (Fluka), Munich 
PBS       Gibco BRL, Karlsruhe 
Potassium dihydrogen phosphate   Merck Eurolab, Darmstadt 
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Propidiume iodide     Sigma, Munich 
SAG-Mannitol solution    Baxter S.A. (Fenwal), Maurepas, France 
Sodium butyrate    Sigma, Deisenhofen 
Spiroepoxide      Alexis, Gruenberg 
Sphingomyelinase (50 U)    Biomol, Hamburg 
1-Stearoyl-2-arachidonoyl-sn-glycerol Alexis, Lausen, Switzerland 
Syto16 (1mM in DMSO)    Invitrogen (Molecular Probes), Karlsruhe  
Sorbitol      Sigma, Deisenhofen 
Stock materials 
6-, 12-, 24- & 96-well plates    Greiner Bio-One, Frickenhausen  
Bottle-top filters for 0.125 l     Millipore, Schwalbach 
Bottle-top filters for 0.25 and 0.5 l  Carl Roth, Karlsruhe 
CryoTube Vials 2.0 ml    Greiner Bio-One, Frickenhausen 
EDTA tubes      Monovette, Sarstedt 
FACS tubes      Greiner Bio-One, Frickenhausen  
Falcon tubes      Greiner Bio-One, Frickenhausen 
Microcentrifuge Filters Ultrafree-MC,  
NMWL 5.000 Dalton, PLCC  
cellulosic membrane    Sigma, Taufkirchen 
MµlTI Twist Top Vials  (1.7 ml;  
10 x 45 mm polypropylene)   Roth, Karlsruhe 
MµlTI Twist Top Vial Caps    Roth, Karlsruhe  
Syringe sterile filter (0.22 µm) Millipore, Schwalbach 
Scintillation vials     PerkinElmer (LAS), Rodgau-Juegesheim 
Tissue culture flasks    Nunc, Wiesbaden 
Transfer pipettes, polyethylene, extended 
fine tip, large bulb, Bulb: 3 ml, sterile  Sigma, Deisenhofen 
Tissue culture flasks     Greiner Bio-One, Frickenhausen 
98 
 
Devices 
Adapter for gas dosing unit EC  
for 24 Pasteur pipettes (V826.612.000) VLM, Leopoldshöhe 
Autoclave (with outlet air bacterial filter) Systec Labor Systemtechnik, Wettenberg  
8-channel-multi-pipette Research pro Eppendorf, Hamburg 
Bath sonicator (Transsonic 310)                   Elma, Singen 
Biofuge pico Heraeus     Kendro laboratory products, Hanau 
β-scintillation counter Wallac 1409      PerkinElmer (LAS), Rodgau-Juegesheim 
Concentrator 5301    Eppendorf, Hamburg 
Dissolved Oxygen Meter (DO-5509)  Lutron, Copersburg, PA, USA 
Horizontal DMZ puller    Zeitz, Augsburg 
Evaporator EVA-EC1-24-S (V832.000.002) VLM, Leopoldshöhe 
FACS Calibur     Becton Dickinson, Heidelberg 
Hamilton microliter syringe(100 µl, 250 µl) Carl Roth, Karlsruhe  
Hera cell incubator 37 °C    Kendro Laboratory Products, Langenselbold 
Heraeus Sepatech Centrifuge   Kendro laboratory products, Hanau 
Light microscope Leica CM E   Leica, Solms 
Rotina35 centrifuge     Hettich GmbH & Co KG, Tuttlingen 
Safety cabinet class II (Hera Safe)   Kendro Laboratory Products, Langenselbold 
Scanning Spectrophotometer   Thermo Electron, Bremen   
Thermomixer 5436     Eppendorf, Hamburg 
Media, buffers and solutions 
Solutions for preparing human erythrocytes for storage 
 Citrate-Phosphate-Dextrose-Stabilizer  (g/l aqua ad iniectabilia)  
 Citrate acide – monohydrate     3.27  
 Sodium citrate – monohydrate    26.30  
 Sodium dihydrogen phosphate – dehydrate  2.50  
 Dextrose monohydrate     25.50   
99 
 
 SAG-Mannitol solution     (g/l) 
 NaCl       8.77  
 Dextrose monohydrate (D (+) – glucose)  9.00  
 Adenine      0.169 
 Mannitol      5.25  
Citrate-Phosphate-Dextrose-Stabilizer (70 ml) and SAG-Mannitol (SAGM) solution (110 
ml) were obtained sterile in pockets connected by thin tubes, separated by a leukocyte 
filter, ready for a blood donation of 500 ml. 
 Sterile saline solution     (in mM): 
 NaCl        150  
 KCl         5  
 CaCl2       1.4 
 
 MgCl2       1 
 HEPES/NaOH pH 7.4     10 
 Glucose      10  
The saline solution was prepared according to Egee et al. {Egee, 2002 484 /id}. The pH 
was adjusted to 7.4 and the osmolarity to 320 ± 5 mOsm (kg H2O)-1 before sterile filtering 
the saline solution through a filter unit of 0.22 µm pore size. 
Media and solutions for the maintenance of P. falciparum in vitro culture  
 Supplemented RPMI 1640 medium  
 HEPES/NaOH      25 mM 
 Gentamicin sulphate     20 µg /ml 
 Glutamine      2 mM 
 Hypoxanthine      200 µM 
 Albumax IITM      0.5 % 
1 M sterile filtered CaCl2 (0.22 µm pore size) was used for preparing human serum from 
plasma. 
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 Albumax stock solution 10 x    (in g/l): 
  Instamed RPMI 1640 with Glutamine 
 NaHCO3       10.43 
 HEPES       5.96 
 D (+) glucose       2 
 Hypoxanthine      0.2 
 Albumax IITM       50 
 Gentamicin sulphate      0.01 
The pH was adjusted to 7.1 - 7.4. The sterile filtered Albumax stock solution was stored in 
50 ml aliquots at -20 or – 80 °C.  
 
 Freezing solution      (in %) 
 Glycerol      28 
 Sorbitol       3 
 NaCl       0.65  
The freezing solution was sterile filtered (through 0.22 µm pore size) and stored at 4 °C. 
 
 Defreezing solution      (in %) 
 NaCl          3.5 
The sterile filtered defreezing solution (through 0.22 µm pore size) was stored at room 
temperature (RT). The solution was warmed up to 37 °C before use. 
 
Solutions to analyze blood smears of P. falciparum infected RBCs 
 Dipotassium hydrogenphosphate    1 M  
 Potassium dihydrogenphosphate    1 M 
Potassium phosphate buffer of pH 7.2 0.1 M was prepared according to Sambrook et al. 
{Sambrook, 1989 1205 /id}. GIEMSA staining solution was freshly prepared from the 
purchased GIEMSA staining solution by dilution 1:10 with 0.1 M potassium phosphate 
buffer pH 7.2, filtered over a paper filter. 
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Solutions for P. falciparum in vitro growth assays 
All solutions were sterile filtered (through 0.22 µm pore size) and added to the 
supplemented RPMI1640 media. Changes in media concentration resulting from the 
addition of solutions were tolerated up to a concentration loss of 10%. In cases where the 
addition of the stock solution to the RPMI medium would have diluted the supplemented 
RPMI medium by more than 10%, the relevant chemical was added directly to the 
supplemented medium, which was then sterile-filtered again. 
For the test solutions the different stock solutions or chemicals were diluted with sterile 
distilled water to obtain the final concentrations shown below. 
 
 Stock solutions (1 M): 
 CaCl2        
 KCl        
 NaCl        
 Na-gluconate       
 NMDG-Cl titrated with HCl to pH 7.4   
 D (+) glucose      
 HEPES (titrated with TRIS (Trizma base) or with NaOH to pH 7.4)  
 
 Synchronization solution     (in mM) 
 Sorbitol isosmotic (5%)     290 
 HEPES / NaOH pH 7.4      10 
 Glucose        5 
When erythrocytes were to be used further, e.g. for western blots (membrane proteins) or 
for measuring 45Ca2+ uptake, the 5% sorbitol solution was supplemented with HEPES and 
glucose. This was done to prevent infected RBCs from being stressed or oxidized through 
glucose depletion. 
 
 Ca2+- Ringer             (in mM) 
 NaCl       140 
 KCl        5 
 HEPES       10 
 MgCl2        1 
 CaCl2           1 
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 Glucose        5  
 Hyperosmolar Ca2+- Ringer     (in mM) 
 NaCl       140 
 KCl        5 
 HEPES       10 
 MgCl2        1 
 CaCl2           1 
 Glucose        5  
 Sucrose      650  
  
 NaCl test solution        (in mM) 
 NaCl        120  
 HEPES / TRIS (titrated with TRIS to pH 7.4) 30 
 KCl       5 
 Glucose      5 
 CaCl2        1.7 
  
Solutions for fluorescence assisted cell sorting (FACS) analysis 
 
 Annexin binding buffer     (in mM) 
 NaCl        140 
 HEPES / NaOH pH 7.4     10 
 CaCl2       5 
 
 PBS         (in M) 
 NaCl        0.14 
 PO4 Buffer pH 7.4     0.01 
 KCl        0.0003  
Each tablet of 5 g PBS had to be dissolved in 500 ml distilled water, giving a final pH 7.45. 
  
Syto16 was diluted before use in a dark environment in PBS or annexin binding buffer to a 
final concentration of 10 nM - 1 µM. 
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Appendix II 
Protocol (1): Preparation of human and mouse erythrocytes (Washing of RBCs) 
1. Take fresh heparinised blood from the transfusion centre.  
2. Transfer the heparinised blood into the 50 ml falcon tube and centrifuge it at 
2600 rpm for 4 min without any break. 
3. Separate the plasma from the cells in the falcon tube. 
4. Now add double volume of RBC wash to the cells in the falcon tube and gently 
mix it. 
5. Again centrifuge the mixture at 2600 rpm for 4 min. 
6. Repeat 4th and 5th steps for three times… 
7. Finally store the washed RBC in the 4oC for further experimental procedures. 
Protocol (2) Infection of washed RBCs with Plasmodium falciparum 
Check the parasitemia of the culture flask in the FACS machine using Syto 16  
1. Take into account what percent of parasitemia is needed for experimentation. 
2. Split the culture into the new sterile flasks 
I. Remove the supernatant from the old flask so that the dead RBC and the 
metabolic wastes of the pathogen may be cleared off. 
II. Gently tilt the flask and measure the pellet volume in the flask (M). 
3. Follow the practical protoco 
Calculations:  
 
Then, 
 
 
 
 
Amount of old culture to be added from the old culture flask… 
  = OB/500µl x M 
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Procedure: 
1. In the laminar flow hood, label sterile culture flasks clearly. 
2. Add 25 ml RPMI complete into the labelled culture flasks. 
3. Add calculated amount of fresh blood to each labelled flask. 
4. Add the calculated amount of old blood from the old culture flasks into the new 
culture flasks. 
5. Gently tilt the flasks. 
6. Gas the culture flasks with 5% CO2, 5% O2 and 90% N2 for 1 min. 
7. Finally incubate the culture flasks at 37oC. 
 
 
Protocol (3): Thawing parasite and culture  
1. Take a 15 ml sterile falcon tube. 
2. Adjust the water bath for 37oC. 
3. Take one parasites cryotube from the liquid nitrogen and thaw at water bath for 5 
min 
4. Spray the disinfectant on the thawed tube. 
5. Gently uncap the tube, with the help of a pipette collect the thawed blood and add it 
into the 15ml falcon tube. 
6. Discard the thawed tube. 
7. Centrifuge the 15 ml falcon tube with thawed blood at 1800 rpm for 4 min. 
8. Remove the supernatant from the falcon tube. (if there is no supernatant remove the 
blood till there is at most 500µl of it left in falcon tube) 
9. Add equal amount of sterile 3.5% sodium chloride solution drop/sec into the falcon 
tube. (This kills all other cells but keeps alive the parasites.) 
10. Mix gently and then centrifuge at 1800 rpm for 4 min. 
11. Wash the pellet with RPMI normal twice to remove the traces of sodium chloride 
and maintain the tonicity of the solution. 
12. Estimate the pellet and remove the supernatant, now add almost excess double the 
volume of RPMI normal to the volume of pellet and mix gently  
13. Centrifuge the falcon at 1800 rpm for 4 min. 
14. Remove the supernatant. 
15. Suspend the pellet in 3 ml of RPMI complete medium. 
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16. Transfer 12 ml of the RPMI complete medium into the cultured flasks. 
17. Add 180µl of fresh blood to the culture flask. 
18. Add the pellet to the cultured flask. 
19. Gas the culture with 5% CO2, 5% O2 and 90% N2 for 1 min. and keep in the BOD 
for incubation. 
 
 
Protocol (4): Isosmotic sorbitol synchronization of P. falciparum infected human 
erythrocytes for in vitro growth assay or DNA amplification and double staining 
Select low parasitemia culture (3-5%) for in vitro growth assay or a high parasitemia 
culture (20-30%) for DNA amplification and double staining techniques. (double staining 
to detect PS exposure). 
1. Remove the supernatant from the selected culture flask 
2. Collect the blood in the sterile 50 ml falcon tube. 
3. Centrifuge the falcon tube at 2000 rpm for 4 min. 
4. Remove the supernatant an estimate the volume of the pellet. 
5. Add 5ml of sorbitol to 500µl of pellet. (Synchronisation) only the ring stages and 
non- infected RBC are left out. 
6. Transfer the pellet sorbitol mixture in to 25 ml falcon tube. 
7. Put on the Wave Tec machine for synchronisation up to 20 min. 
8. Again centrifuge the falcons at 2000 rpm for 4 min. 
9. Remove the supernatant and add 10 ml of normal RPMI-1640 medium to remove 
the remaining sorbitol (the tube containing only ring stages and non-infected RBC). 
10. Centrifuge again for 4 min at 2000 rpm. 
11. Transfer the pellet into the small eppendorf tube and wash again the ring stages and 
non-infected erythrocytes with normal RPMI-1640 medium and centrifuge at 2000 
rpm for 2 min. 
12. Remove the supernatants from the eppendoff tube and mix the pellet gently. 
13. Keep the eppendoff tube in the refrigerator at 4oC. 
14. Now the pellet is ready for DNA amplification and double staining. 
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Protocol (5) In vitro growth assay 
Selection of low parasitemia culture (3-5%) for in vitro growth assay technique. 
1. Remove the supernatant from the selected culture flask 
2. Collect the blood in the sterile 50 ml falcon tube. 
3. Centrifuge the falcon tube at 2000 rpm for 4 min. 
4. Remove the supernatant and estimate the volume of the pellet. 
5. Add 5ml of sorbitol to 500µl of pellet. (Synchronisation) only the ring stages and 
non- infected RBC are left out. 
6. Transfer the pellet sorbitol mixture in to 25 ml falcon tube. 
7. Put on the Wave Tec for synchronisation up to 20 min. 
8. Again centrifuge the falcons at 2000 rpm for 4 min. 
9. Remove the supernatant and add 10 ml of normal RPMI-1640 to the falcon and 
wash the ring stage. 
10. Centrifuge again for 4 min at 2000 rpm. 
11. Transfer the pellet into the small eppendorf tube and wash again the erythrocytes 
with normal RPMI-1640 and centrifuge at 2000 rpm for 2 min.  
12. Remove the supernatants in the eppendoff tube. 
13. Keep the eppendorf tube in the refrigerator at 4oC. 
14. Now the pellet is ready for in vitro growth assay. 
 
Procedure: 
1. Collect the low parasitemia blood pellet and store in the refrigerator in 4oC. 
2. Label the required 12ml PP-tubes according the drug concentrations. 
3. Put 2 ml of complete RPMI into each labelled PP-tubes. 
4. Add respective drug concentrations in to the RPMI containing labelled PP-tubes. 
5. Vortex the falcons for homogenous mixture of the drug in the RPMI. 
6. Add 20 µl of low parasitemia blood pellet to the above falcons and mix gently with 
a pipette. 
7. Take a sterile 96 well plate and label it. 
8. Put 200µl of the RPMI+ high parasitemia blood pellet + drug into each well. Avoid 
the bubble formation in the wells. 
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9. Incubate for 48 hrs in the candle jar in the BOD. 
10. After 48 hrs, take slowly the incubated 96 well plate and gently mix the culture in 
each well. 
11. Take 50µl of the culture from wells of each concentration and put in labelled 
FACS falcon tubes. 
12. Now add 200µl of PBS + EDTA with Syto-16 to each falcon tube and incubate 
for 20 min. 
13. Analyse the sample with FACS machine. 
 
Protocol (6): Measurement of percentage parasitemia by Syto-16 
1. Preparer the required amount of BPS containing Syto 16 by the ratio of 1000:1 (the 
volume of BPS required for each tube is 250 µl.) 
2. Label the FACS (Fluorescence Activated Cell Sorting) tubes. 
3. Take small amount (~20 µl) of infected blood from the cultured flasks. 
4. Add Syto-16 to PBS with Syto 16 to FACS tube containing infected blood and 
vortex. 
5. Incubate the FACS tubes in the BOD (Biochemical Oxygen Demand) 37oC for 30 
min. 
6. Estimate the percent parasitemia in each cultured flasks with the help of FACS 
machine. 
 
Protocol (7): Giems staining technique 
1. Put a drop of sample on a clean and sterile slide with the help of transferring 
pipette. 
2. Make a thin film smear on the slide with the help of another slide 
3.  Air dry the smear on the slide. 
4. fix the smear in methanol for 1 min.(by sprinkling few drops on the smear) 
5. Dry again the slide and immerse the slide in Giems + May Grinwald (10+90 
ml) mixture for 30 min. 
6. wash the slide gently under running tap water and observe under the 
microscope at 100X 
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Protocol (8): Annexin binding experiments (Determination of phosphatidylserine 
exposure by double staining technique) 
1. Collect the high parasitemia blood pellet and store in the refrigerator in 4oC. 
2. Label the required 12 ml PP-tubes according to the drug concentrations 
required. 
3. Put 2 ml of complete RPMI into each labelled falcon. 
4. Add respective drug concentrations in to the RPMI containing labelled PP-
tubes. 
5. Vortex the falcons for homogenous mixture of the drug in the RPMI. 
6. Add 20µl of high parasitemia blood pellet to the above PP-tubes and mix gently 
with a pipette. 
7. Take a sterile 96 well plate and label it. 
8. Put 200µl of the RPMI+ high parasitemia blood pellet+ drug into each well. 
Avoid the bubble formation in the wells. 
9. Incubate for 24 hrs in the candle jar in the BOD. 
10. After 24 hrs, take slowly the incubated 96 well plate and gently mix the culture 
in each well. 
11. Take 50µl of the culture from any of the two wells from each concentration and 
put in labelled eppendorf tubes. 
12. Add 200µl of annexin wash buffer to each eppendorf tube and mix well. 
13. Centrifuge at 2000 rpm for 5 min. 
14. Remove the supernatant with help of a vacuum pump and retain the pellet. 
15. Add 5µl of annexin APC to each pellet and mix. 
16. Add 100 µl of annexin wash buffer with syto-16 to each eppendorf tube and 
incubate for 20 min in the incubator. 
17. Transfer the incubated mixture into small falcons and add 100µl of annexin 
wash buffer to each small falcon before analysing with FACS. 
18. Prepare some extra single stain samples for each syto-16 and annexin for 
adjusting the settings for FACS. 
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Protocol (9): Haemolysis test 
1. Prepare 6 samples each containing 12.5 µl of pellet containing 5% of 
hematocrit. (total pellet required for 6 samples is 75 µl) 
2. Add 200 µl of ringer to each sample in sterile eppendorf.(total ringer required is 
1200 µ) 
3. Incubate the samples in the incubator for 24 hrs at 37 oC. 
4. After incubation gently tilt the samples and centrifuge for 5 min at 2000 rpm. 
5. Collect the supernatant and transfer it into cuvettes. 
6. Add 550µl of transferring reagent to each sample. 
7. Prepare a standard curve using control samples. 
a. After removing the supernatant from the eppendorf add 200µl of 
millipore water and gently mix. 
b. Transfer it into another eppendorf and add 200 µl of millipore water. 
c. Make the required concentrations to establish a standard curve. 
8. Measure the absorbance of the samples in cuvettes at 546 nm using    
spectrophotometer. 
Protocol (10): Preparation of RPMI complete medium 
Requirements: 
Glutamine (2 mM)    5 ml 
HEPES/ NaOH pH 7.4 (25 mM)  12.5 ml 
Gentamycin (20µg/ml)   0.5ml 
Albumax (0.5%)    50 ml 
1. Take fresh RPMI-1640 from the cold room, falcon of 50 ml albumax 10X from 
refrigerator and 5 ml of glutamine from -20oC, allow to worm in the water bath 
to 37oC.  
2. Take glutamine from the -20 oC refrigerator. 
3. In the laminar flow hood, gently mix albumax and glutamine with the worm 
RPMI-1640.  
4. Then add 12.5 ml HEPES and 0.5 ml Gentamycin  
5. Mix well. 
6. Store now the RPMI complete medium in 4oC for further experimental 
procedures. 
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Protocol (11): Preparation of RBCs wash solution 
Requirements: 
150 mM NaCl (54.44)    8.166 g 
5 mM KCl (74.55)   0.3727 g 
1.4 mM CaCl2 (110.98)  0.15537 g 
1 mM MgCl2 (95.21)     0.09521 g 
10 mM HEPES (238.30)  2.38 g 
10 mM Glucose (198.17)   .9817 g 
 
1. Weigh accurately all the required chemicals and put in a sterile 1000 ml bottle. 
Then add millipore distilled water. (mix with magnetic stirrer to homogenise the 
solution ) 
2. Adjust the pH of the solution upto7.4, initial pH will be up to 5.34 then add 1M 
NaOH to make it 7.4. 
3. Then check the osmolarity. 
4. Calibrate the osmolity with 290 and 1000 then check the osmolity of the RBC 
wash solution. It must be within 290-310. (If slightly above 310 add normal 
distilled water to adjust.) 
5. After preparation of the homogenous solution filter it with millipore (0.22µM) 
using vacuum in sterile conditions. 
6. Now store it in clean and dry place. 
 
 
 
